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different embryologic origins, reside in ECMs of diverse compositions, and are exposed to various mechanical
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stiffness may be conserved across species and cell types, and that stiffness significantly dictates VSMC
transcriptional identity over contributions from embryologic origins. However, we also discovered instances
of origin-specific stiffness responses in stiffness-mediated lncRNA expression and stiffness-mediated splicing.
We identified a highly correlated network of adjacent stiffness-sensitive lncRNAs-protein coding gene pairs,
which led us to experimentally interrogate the lncRNA PACER as a regulator of stiffness-mediate expression.
We surprisingly found that PACER’s previously established regulatory pathway is absent in VSMCs. Using
enrichment methods, we identified TBX5 and show that it is a stiffness-sensitive transcription factor specific
to Co VSMCs. We also demonstrated a new role for MALAT1 as a lncRNA regulator of stiffness-dependent
VSMC proliferation and migration. Thus, this dissertation reveals many novel characteristics of the VSMC
stiffness-regulated transcriptome that may have clinical utility in understanding and managing the
pathogenesis of arterial stiffening.
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ABSTRACT 
REGULATION OF THE HUMAN VASCULAR SMOOTH MUSCLE CELL TRANSCRIPTOME BY 
EXTRACELLULAR MATRIX STIFFNESS 
Christopher Yu 
Daniel J. Rader, M.D. 
Richard K. Assoian, Ph.D. 
Arterial stiffness is a risk factor for several cardiometabolic diseases and is caused by 
pathological remodeling of the vascular extracellular matrix (ECM). Vascular smooth 
muscle cells (VSMCs) respond to ECM stiffness by proliferating, migrating, and further 
remodeling the vascular ECM, thus contributing to vascular disease like atherosclerosis 
and hypertension. VSMCs along the vasculature are highly diverse as they arise from 
different embryologic origins, reside in ECMs of diverse compositions, and are exposed 
to various mechanical forces. This dissertation aims to understand how ECM stiffness 
regulates the transcriptional response of VSMCs from different origins, namely aortic 
(Ao) and coronary (Co) VSMCs. We conducted deep sequencing of RNA from Ao and 
Co VSMCs grown on engineered polyacrylamide hydrogel surfaces tuned to physiologic 
and pathologic stiffness. Using several bioinformatic approaches, we compared the 
transcriptional landscapes in Ao and Co VSMCs by looking at whole-gene level 
expression, splicing, and conservation properties, with a focus on long non-coding RNAs 
(lncRNAs), as they compose a significant portion of the unexplored VSMC 
transcriptome. We found evidence suggesting that the overall transcriptional response to 
stiffness may be conserved across species and cell types, and that stiffness significantly 
dictates VSMC transcriptional identity over contributions from embryologic origins.  
However, we also discovered instances of origin-specific stiffness responses in stiffness-
mediated lncRNA expression and stiffness-mediated splicing. We identified a highly 
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correlated network of adjacent stiffness-sensitive lncRNAs-protein coding gene pairs, 
which led us to experimentally interrogate the lncRNA PACER as a regulator of stiffness-
mediate expression. We surprisingly found that PACER’s previously established 
regulatory pathway is absent in VSMCs. Using enrichment methods, we identified TBX5 
and show that it is a stiffness-sensitive transcription factor specific to Co VSMCs. We 
also demonstrated a new role for MALAT1 as a lncRNA regulator of stiffness-dependent 
VSMC proliferation and migration. Thus, this dissertation reveals many novel 
characteristics of the VSMC stiffness-regulated transcriptome that may have clinical 
utility in understanding and managing the pathogenesis of arterial stiffening. 
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CHAPTER 1: INTRODUCTION  
Clinical Importance of Vascular Stiffening 
Arterial stiffening is a long-recognized mechanical property important in cardiovascular 
health. Arterial stiffness has been under investigation since the early 19th century, when 
Thomas Young, who was a physician and physicist, quantified heart and arterial stiffness 
and derived Young’s (elastic) modulus, a now generalizable material property1. Arterial 
stiffening is a natural result of aging2–4 and is a risk factor for and consequence of 
multiple cardiometabolic diseases including hypertension, atherosclerosis, coronary 
artery disease, stroke, diabetes, renal disease, and all-cause cardiovascular mortality2,5–
15. Clinically, arterial stiffness is measured indirectly using surrogate parameters such as 
pulse pressure and pulse wave velocity (the gold standard), or through 
pressure/diameter measurements using magnetic resonance imaging14.  
Clinical Risk Factors for Arterial Stiffening 
Although arterial stiffness is measurable and highly predictive of disease, there are no 
therapies targeting stiffness directly and management focuses on addressing modifiable 
risk factors such as lifestyle modifications16, smoking17, dyslipidemia18, diabetes and 
hypertension19,20. Age and genetic factors contribute to arterial stiffness. Arterial 
stiffening progresses with aging, with inflections during puberty and menopause, and 
further accelerates into older age. At advanced ages, males also have a higher rate of 
progression of arterial stiffening than females2–4,21. Analysis of several hundred families 
in the Framingham Heart Study cohort found that arterial stiffness is a heritable trait14 
and subsequent genome-wide association studies have linked several arterial stiffness-
associated traits such as pulse pressure and pulse wave velocity to single nucleotide 
polymorphisms (SNP)22–24. Several monogenic disorders also result in altered vascular 
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biomechanics and premature stiffening such as mutations in FBN1 (fibrillin-1, leading to 
Marfan’s syndrome)25,26, mutations in ELN (elastin, leading to Willam’s syndrome and 
supravalvular aortic stenosis)27, and LMNA (lamin A, leading to progeria)28.  
Mechanism of Vascular Stiffening 
Tissue stiffening is a hallmark of aging and disease in many organ systems not only 
arterial vasculature. In general, tissue stiffening results from cellular remodeling of the 
extracellular matrix through increased deposition and crosslinking of matrix proteins, but 
also through changes in matrix components. In the vasculature, both changes in matrix 
stiffness, intrinsic cellular stiffness and cell contractility/tone contribute to arterial 
stiffening.  
Extracellular Matrix Contributions to Stiffness 
During development, the vasculature is formed from a primitive endothelial plexus that 
rearranges to form lumens and branches and subsequently recruits vascular smooth 
muscle cells (VSMCs). These VSMCs interact with the developing vasculature by 
depositing concentric layers of extracellular matrix (ECM). VSMCs secrete a myriad 
collection of ECM proteins (e.g. collagens, elastin, and proteoglycans), crosslinkers (e.g. 
lysyl oxidases), and matrix-metalloproteinase. The basis for vascular wall stiffness is 
formed from the balance and organization of these ECM proteins (e.g. fibrillar collagens 
provide load bearing tensile properties, while elastin provides elastic properties). VSMCs 
only deposit and crosslink elastin during the postnatal period, thus the elastic properties 
of the vascular wall are, in a sense, afforded only early in development. Through aging 
and disease, elastin progressively degrades without replenishment and fibrillar collagens 
are extensively deposited, leading to imbalances in the ECM and progressive 
stiffening29–31. 
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Biomechanical studies suggest that the collagen/elastin ratio of the vessel wall 
significantly determines arterial stiffness. At physiologic pressures/distension, the vessel 
wall resides in an elastic regime dominated by elastin. As degradation occurs, the same 
pressures and distension shift into a stiffer regime dominated by collagens30,31. The loss 
of elastin occurs naturally during aging and is accelerated in several pathologic states. 
This occurs through the upregulation of matrix-metalloproteinases (e.g. MMP-2, -9, -12) 
which directly degrade elastin resulting in fragmentation, disorganization, and increased 
arterial stiffness32,33. Human mutations in the elastin and fibrillin-1, a scaffold for elastin, 
result in severely reduced and disorganized elastic lamina resulting in premature arterial 
stiffening. In osteogenesis imperfecta, mutations in collagen I are associated with loss in 
tensile properties leading to aortic root dilatation and aortic valve insufficiency, coronary 
artery dissection, and aneurysms34–37. 
 
Cellular Contributions to Stiffness 
In addition to the material properties of the ECM, properties of vascular cells also 
contribute significantly to overall arterial stiffening. During adulthood, VSMCs can exist in 
a continuum of phenotypes between a “differentiated/contractile” state and a “de-
differentiated/synthetic” state. Under normal physiologic conditions, VSMCs are thought 
to be in a predominantly contractile state where they are non-proliferative, non-secretory, 
and primarily function to regulate vascular tone and blood flow. During disease, VSMCs 
can de-differentiate into the synthetic state, gaining proliferative and migratory capacity 
as well as secreting and crosslinking new ECM, such as fibrillar collagens and 
fibronectin, but not elastin, promoting vascular wall hypertrophy, luminal narrowing, and 
stiffening38.  
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Endothelial cells lining the arterial lumen serve many roles as a protective barrier and 
regulator of vascular homeostasis. Endothelial cells release potent vasoactive factors 
such as nitric oxide and endothelin-1 that control VSMC tone and also prevent VSMC 
dedifferentiation into the synthetic phenotype39,40. During disease, endothelial 
dysfunction occurs resulting in loss of the protective barrier function, leading to 
inflammation and dysregulated VSMCs. Pathologic increases in vascular tone, VSMC 
contractility, and thus intrinsic VSMC stiffness, contribute to total vascular wall 
stiffness41,42. Endothelial and VSMC dysfunction can also result from chronic exposure to 
elevated blood glucose, inflammation and renin-angiotensin signaling underlying the 
association of arterial stiffness with diabetes, hypertension, and renal dysfunction19.  
 
Lastly, arterial stiffening is both a cause and consequence of arterial stiffness. Synthetic 
substrates mimicking pathologic stiffness increased endothelial cell inflammatory 
markers and increased VSMC expression of matrix proteins and crosslinkers43–45. 
Several in vivo models are consistent with this positive feedback mechanism of arterial 
stiffening begetting more stiffening. In an obese mouse model, diet-induced arterial 
stiffening measured by pulse wave velocity preceded elevated systolic blood pressures 
and matrix expression9. This phenomenon was similarly seen in rat models of pulmonary 
hypertension and liver fibrosis, where matrix stiffness, measured by atomic force 
microscopy, preceded further matrix remodeling and fibrosis45,46.  
Mechanotransduction: How Cells Sense Stiffness 
The vasculature is constantly exposed to mechanical stimuli that are critical to vascular 
morphogenesis and function: cyclic stretch, shear stresses, hydrostatic pressure, and 
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microenvironmental stiffness. Vascular cells sense these external stimuli through a 
series of mechanotransduction events including membrane bound receptors for cell-
matrix adhesions (integrins), cell-cell adhesions (cadherins), cell-fluid flow interfaces 
(e.g. VEGFR2/PECAM-1/VCAM47), and stretch-sensitive receptors (e.g. ion-channels 
48,49). Cells then integrate these external stimuli through a series of downstream 
signaling events leading to changes in cellular phenotype. I will focus primarily on 
mechanotransduction events specific to matrix stiffness-sensing, as it is the focus of this 
thesis, but the contributions of the other aforementioned mechanical forces are of equal 
significance in vascular physiology and disease.  
 
Much like how we pull on an object with more or less effort to perceive its 
resistance/stiffness, early studies in the 1980-1990’s visualized and quantified cellular 
traction forces50–52 and developed platforms to directly show that cells can sense an 
external substrate’s resistance to intracellularly-generated traction forces53,54. Notably, 
Pelham and Wang developed a collagen-coated polyacrylamide hydrogel substrate, still 
extensively used in stiffness-sensing studies today, that is ideally elastic, can span 
physiologic to pathologic elastic moduli, and most importantly precisely control matrix 
stiffness while keeping cell-adhesion density constant. Their original study showed that 
matrix stiffness controlled focal adhesion formation, and since then, several other 
tunable stiffness platforms have been engineered using other natural and synthetic 
polymers to understand cell stiffness-sensing and response. 
 
Critical to stiffness-sensing is the ability of the cell to engage the ECM through integrins. 
Integrins are a family of heterodimeric, transmembrane proteins that directly bind to 
ECM proteins and can become activated upon engagement and with applied force. The 
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activation of integrins results in a complex cascade of intracellular signaling events, in 
constant feedback, that trigger the formation and maturation of focal adhesions which 
physically link the ECM to the internal actin cytoskeleton. Small RhoGTPases (e.g. 
RhoA, Rac1) are activated during this process and promote further organization of the 
cytoskeleton through increased actin-myosin generated forces. The forces propagate 
inwards to the nucleus through the LINC (linker of nucleoskeleton and cytoskeleton) 
complex but also back out toward the integrin/focal adhesion complex, resulting in a 
feedback control loop of further integrin activation until cell generated forces and 
resistive forces from the matrix are balanced and tensional homeostasis is achieved. At 
pathologic stiffness, this process is greatly altered and tensional homeostasis can be 
disrupted55–58.  
 
The initial events in force propagation occur rapidly and do not require changes in gene 
expression or new protein synthesis as the acute response utilizes already present 
cellular components in a series of second messenger, phosphorylation, polymerization, 
and nucleotide-exchange events. However, the initial events ultimately result in longer 
time-scaled transcriptional changes that ultimately govern critical cellular processes like 
proliferation and differentiation, and also induce further expression of focal adhesion and 
cytoskeletal genes. These transcriptional changes occur at several levels involving 
transcription factors in the immediate early response, and regulation at the epigenetic 
(e.g. histone modification) and post-transcriptional level (e.g. microRNA). Several of 
these processes will be discussed below. 
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Mechanotransduction: Transcriptional Response 
Forces generated from stiffnesss-sensing and stretching were found to repress gene 
expression through PRC2 (polycomb-repressor complex 2)-mediated histone 
modifications (e.g. H3K27me3 and H3K9me2,3). These led to heterochromatin and 
transcriptional silencing of several mechanosensitive genes, and this effect was 
dependent on transduction through LINC complex proteins (e.g. nesprins, lamins, and 
emerin)59–61. These forces not only influence chemical modifications of chromatin, but 
can also physically stretch, position, and de-condense chromatin to enable transcription 
62,63. Furthermore, the nucleus itself contains mechanosensitive elements and like the 
cytoskeleton, the nucleoskeleton responds by stiffening in response to applied force64. 
 
Several mechanosensitive transcription factors have been described. MAL (MRTF-A or 
MLK1) is a transcriptional co-activator that potentiates the activity of serum response 
factor (SRF) to regulate expression of genes in myogenesis65. YAP/TAZ are also 
transcriptional co-activators that potentiate the activity of TEAD transcription factors to 
regulate proliferation and differentiation66. Both YAP/TAZ and MAL nuclear localization 
are regulated by stiffness-driven actin polymerization and nucleoskeletal/cytoskeletal 
tension64,67–69. NF-kB also responds to matrix stiffness70 and has been extensively 
observed in response to shear stresses, requiring Rho-GTPase activity (Rac1) and 
cytoskeletal organization71. Gene targets of early transcription factor activation may also 
feedback to further strengthen upstream mechanotransduction events such as the 
transcription of focal adhesion complex proteins72. 
 
Matrix stiffness also regulates gene expression co- and post-transcriptionally. In breast 
tumors and endothelial cells, the expression of fibronectin-EDB, VEGF-165b, and PKC-
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βII isoforms are upregulated by matrix stiffness via activation of serine/arginine rich (SR) 
splicing factors73. MicroRNAs (miRNAs), a class of short non-coding RNAs that target 
mRNAs for degradation, also control the post-transcriptional response to stiffness. For 
example, matrix stiffness increases miR-18a to reduce levels of its targets (e.g. PTEN) 
contributing to malignant phenotypes in breast cancer74. miR-203, which is inhibited by 
stiffness in breast epithelium, targets ROBO-1/Rac1 to regulate cell contractility and 
focal adhesion complexes75.  
 
Indeed, transcriptional regulation is a complex process. New layers of transcriptome 
properties and classes of regulators are being exponentially discovered due to advances 
in next-generation sequencing technologies and transcriptome-wide bioinformatic 
algorithms. For example, the thousands of recently discovered long non-coding RNAs, 
RNA-modifications/editing, and novel splicing patterns are only beginning to be 
mechanistically implicated in critical cellular functions. As the group of studies discussed 
above have yielded significant insight into mechanotranduction mechanisms, whether 
and how mechanotransduction interfaces with these new transcriptome layers is 
intriguing. 
Specific Mechanotransduction Mechanisms in Vascular Smooth Muscle Cells 
The prior section discussed mechanotransduction events elucidated from multiple 
cellular systems and engineering platforms. Much of these mechanisms are intact in 
VSMCs and will be discussed in detail in this section.  
As briefly mentioned above, changes in ECM material properties and vascular cells 
phenotypes during development and disease can dictate how various mechanical stimuli 
are transmitted to and sensed by cells. For example, changes in vascular stiffness often 
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coincide with changes in vascular wall thickness, luminal diameter, and intimal barrier 
permeability, resulting in altered cell exposure to cyclic wall stresses and fluid shear 
stresses. Again, this section will focus mainly on the VSMC response to matrix stiffness, 
but the role of these other important mechanical forces on VSMCs has been reviewed by 
others76,77. 
ECM-stiffness-dependent VSMC functions 
Early studies using synthetic PEG-hydrogels suggested that matrix stiffness may 
regulate VSMC phenotypic modulation, where increased stiffness favored the synthetic 
phenotype78–80. On polyacrylamide-hydrogels, our lab and others showed that VSMCs 
increased expression of ECM proteins, were more proliferative and motile on stiffer 
matrices, and that VSMC migration was durotactic (i.e. migrating toward increasing 
stiffness)44,45,78,81,82. Matrix stiffness also enhanced the VSMC response to platelet-
derived growth factor and its receptor (PDGF/PDGFR), a potent regulator of VSMC 
phenotypic switching in both development and disease83. VSMC basal contractility (non-
stimulated) and active contractility (vasoagonist-stimulated) were both increased at 
higher stiffness substrates, and this effect was independent to changes in VSMC 
differentiation state84. In vivo stiffness models, such as femoral-wire injury and 
pharmacologic inhibition of lysyl oxidase, were consistent with these in vitro 
findings44,45,81. These studies demonstrate that matrix stiffness regulates key VSMC-
specific processes critical in arterial disease progression. 
Cell-ECM interaction during VSMC stiffness-sensing 
VSMC stiffness-sensing begins with integrin engagement with the underlying ECM 
protein. Different integrins are activated by different ECM proteins and can affect how 
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VSMCs may sense the underlying matrix stiffness, resulting in altered VSMC 
phenotypes85. For example, fibronectin, which is present at low levels in normal arteries 
is elevated during injury and inflammation and engages mechanosensitive integrins (e.g. 
α5β1)
86. Studies which independently changed fibronectin concentrations and substrate 
stiffness showed that the amount of fibronectin dictated stiffness-driven VSMC 
migration78. Furthermore, stiffness-mediated increases in VSMC cytoskeletal tension 
and durotactic migration was greater on fibronectin-conjugated hydrogels than on those 
conjugated with laminin, a “healthy” basement membrane protein typically disrupted 
during disease87–90. Mechanotransduction events through VSMC cell-ECM interactions 
are also influenced and balanced by cell-cell adhesions91,92.  
Intracellular signaling during VSMC stiffness-sensing 
Our lab recently identified a VSMC mechanosensing pathway where stiffness is 
transduced through phosphorylation of FAK, p130Cas and Rac1 to regulate stiffness-
mediated increases in proliferation, cytoskeletal tension, and cellular stiffening93. A 
series of in vitro and in vivo studies also identified a potential positive-feedback signaling 
pathway for matrix stiffening involving cyclooxygenase-2 (COX2) and lysyl oxidase 
(LOX). These studies showed that matrix stiffness increases the expression of LOX, 
collagens, and fibronectin. Stiffness also inhibited COX2 expression, which is necessary 
to suppress stiffness-mediated expression of collagens and fibronectin44,45,94,95. At the 
time of writing this dissertation, a study elucidated that the stiffness-sensitive 
transcriptional co-activator, YAP/TAZ and its DNA-binding partner, TEAD, are necessary 
for stiffness-mediated expression of LOX and COX-2 in VSMCs96. YAP activation also 
interferes with SRF/myocardin transcriptional activity leading to repression of 
contractile/differentiated phenotype genes97.  
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Vascular Heterogeneity 
The arterial vasculature is an extremely diverse active conduit of multiple cell types from 
multiple embryonic origins experiencing multiple environmental forces.  
Vascular bed mechanical property diversity 
Vascular bed mechanical stimuli are extremely diverse along the length of the arterial 
tree: the large diameter aorta contains multiple layers of elastic lamina experiencing 
pulsatile, high pressure, high velocity flow; medium and smaller muscular arteries (e.g. 
coronary and mesenteric arteries) have fewer elastic layers; arterioles experiencing less 
pressures and velocities; and capillaries with laminar non-pulsatile flow are often only 
lined by a single layer of mural cells. These regional differences can also be appreciated 
in the observation that atherosclerotic plaques do not develop uniformly but rather site-
specifically due to differences in local blood flow properties. The compositional balance 
between the different ECM proteins (e.g. collagens, elastins, proteoglycans) is also 
diverse along the vascular bed, contributing to differences in overall mechanical 
properties and cellular responses through differential integrin engagement30,31,98.  
Vascular smooth muscle heterogeneity 
VSMCs arise from various distinct embryologic origins: proepicardium (coronary 
arteries), neural crest (aortic outflow tract-ascending aorta), and somatic and splanchnic 
mesoderm (descending thoracic and abdominal aorta). VSMCs along the vasculature 
are also phenotypically plastic and exist in a continuum of phenotypes ranging from 
“contractile/differentiated” to “synthetic/proliferative” depending on stimuli. As a result of 
differing embryologic origins and exposure to mechanical stimuli, regional variations in 
vascular cell transcriptomes and proteomes exist98–101. For example, VSMCs isolated 
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from different segments of the arterial tree vary in their expression of vasoagonist 
receptors102,103, cytoskeletal proteins, and transcription factors104, and cell stiffness98.  
 
Furthermore, VSMCs have origin-specific responses to biochemical and mechanical 
stimuli: response to vasoagonists102,103, propensity to form calcifications105, proliferation, 
matrix production, integrin expression, and response to TGF-beta106–108. Several studies 
also show that origin-specific VSMC phenotypes and responses may be relatively stable 
and maintain their properties when transplanted to different microenvironments, 
suggesting that VSMC phenotype heterogeneity in vivo may be more genetically 
controlled than controlled by the local microenvironment109–114. Thus, VSMC diversity 
and its implication in disease is complex and covered in several comprehensive 
reviews109,110,115,116.  
 
Most of these lineage-specific VSMC differences and matrix-dependent VSMC 
responses have been elucidated using predominantly non-human cell and animal 
models. Recently, Cheung et. al derived VSMCs representing three distinct origins 
(neural crest, somitic mesoderm and proepicardium/lateral plate mesoderm) using 
human-induced pluripotent stem cells, and demonstrated VSMC-origin-specific 
responses to cytokines and expression patterns of matrix remodeling proteins117. 
Understanding the stiffness-dependent differences in human aortic and coronary 
VSMCs, which arise from the neural crest and proepicardium, respectively, will 
contribute to our understanding of differences in aortic and coronary artery disease and 
will be a goal of this dissertation. 
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Dissertation Goals 
Given the importance of arterial stiffness as a normal consequence of aging and its 
close association to several diseases, the critical role VSMCs play in responding to and 
contributing to pathological matrix stiffening, and regional differences in vascular matrix 
properties and in cellular embryologic origins, this dissertation aims to understand the 
relative contribution of VSMC origin and matrix stiffness in dictating the VSMC 
transcriptome landscape. As the in vivo milieu of matrix stiffening is complex, resulting 
from many mechanical, cellular, and biochemical stimuli, this dissertation will utilize 
polyacrylamide hydrogel substrates to interrogate only the consequences of stiffness. 
Several unbiased approaches will be employed to characterize the VSMC stiffness-
sensitive transcriptome, to identify potential transcriptional regulatory networks in the 
stiffness-response, and to generate several hypotheses that will be subsequently tested. 
A focus will be placed on long non-coding RNAs (discussed in detail in the following 
chapters), as they compose a large portion of the unexplored VSMC transcriptome and 
have been implicated in key cellular processes. 
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CHAPTER 2: CHARACTERIZATION OF THE VASCULAR SMOOTH MUSCLE CELL 
STIFFNESS-SENSITIVE TRANSCRIPTOME 
Introduction 
Recent advances in next-generation sequencing and high-throughput technology has 
enabled the rapid discovery of nucleic acid sequences and modifications found in cells: 
genomes, transcriptomes, epigenomes, methylomes, etc. Unlike microarrays, which only 
allowed for detection of pre-defined targets, next generation sequencing allows for 
unbiased discovery and quantification of both known and novel nucleic acid sequences. 
This has allowed for the rapid expansion of knowledge about the human transcriptome, 
the set of all RNA molecules transcribed from genomic DNA.  
In the last decade, the known human transcriptome has expanded from being 
predominantly composed of protein-coding transcripts to predominantly non-coding 
transcripts. In early 2009, the GENCODE project reported that 47,553 human genes 
were known (15,739 of these genes being non-coding RNAs). By the end of 2016, 
58,219 human genes were known with about 24,355 of those being non-coding RNAs118. 
While this represented an increase of 10,666 known genes, the number of known 
transcripts increased even further from 132,067 to 199,325, representing newly 
discovered isoforms of previously well-studied genes as well as previously unannotated 
genes. While our ability to detect and define novel genes and transcripts have rapidly 
evolved, the vast majority of the transcriptome is still functionally unknown.  
Transcriptome landscapes and determinants of diversity 
Transcriptome landscapes are extremely complex and diverse between cell-types, 
tissue-types, individual organisms, and physiologic-pathologic state. Several efforts have 
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utilized RNA-sequencing to define the transcriptomes of various cell types and tissues 
from thousands of different humans and other organisms (GTEx, ENCODE, NIH 
Roadmap Epigenomics)119–121. These multi-cellular and multi-tissue studies demonstrate 
that there are multiple layers of transcriptome diversity forming the basis of cell, tissue, 
and organism diversity. 
In particular, transcriptome complexity arises partly from cell and tissue-type specific 
gene expression (including transcription factors), alternatively spliced isoforms, 
alternative transcription initiation/termination isoforms, and post-transcriptional RNA 
regulators (e.g. microRNAs and editing)122. Human genomic variations, such as single 
nucleotide polymorphisms (SNPs) and copy number variations (CNVs), also lead to 
transcript diversity in the form of expression quantitative trait loci (eQTL), splicing 
quantitative trait loci (splicing-QTL) and allelic-specific expression (ASE), where a variant 
is statistically correlated to changes in gene expression pattern123.  
As discussed in Chapter 1, the vasculature is heterogeneous across the body, and 
different vascular beds and their VSMCs arise from different developmental origins. 
Multiple studies (including GTEx and NIH Roadmaps Epigenomics)119,121 have profiled 
the transcriptomes of different arteries (e.g. aorta, coronary, tibial), but these data 
represent the expression not only from VSMCs but from all other vascular cells such as 
endothelial cells, macrophages, and fibroblasts. Thus, while the transcriptomes of whole 
vascular tissue from different regions have been interrogated, the transcriptome 
landscapes of origin-specific VSMCs have not yet been explored or directly compared.  
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Long non-coding RNAs 
Long non-coding RNAs (LncRNAs) were among the thousands of newly identified 
transcripts as a result of RNA-sequencing. LncRNAs are defined as transcripts greater 
than 200 nucleotides in length which can be spliced and polyadenylated, but with no 
coding potential. They contribute significantly to transcriptome diversity as lncRNA 
expression patterns exhibit higher cell- and tissue-specificity than protein-coding 
genes124–126. Furthermore, even if their expression is not specific, lncRNA functionality 
can be cell-type specific. A large lncRNA-inhibition screen in multiple cell types identified 
lncRNAs that controlled cell proliferation in only a few cell types, despite being 
ubiquitously expressed in all cell types127.  
 
LncRNAs have been implicated in biological, developmental, and pathological processes 
and act through mechanisms such as chromatin modifications, cis-regulation of target 
genes, and post-transcriptional regulation of mRNA processing125,128,129. Several studies 
have identified VSMC-specific and VSMC-functional lncRNAs such as SENCR, lincRNA-
p21, MYOSLID, and SMILR130–134. These lncRNAs were found to be involved in 
processes such as TGF-β signaling, actin-stress fiber formation, and regulation of 
transcription factors like MAL, suggesting that lncRNAs could play a role in 
mechanotransduction. To my knowledge, no lncRNA has been implicated in the cellular 
response to mechanical stimuli and this chapter serves to identify lncRNAs that respond 
to matrix stiffeness. 
Alternative Isoforms and Splicing 
The expression of alternative gene isoforms is cell and tissue specific135 and significantly 
contributes to proteome diversity136. While the number of known isoforms has also grown 
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exponentially, the functional consequences of most isoforms are unknown. However, in 
contrast to lncRNAs, the mechanism and consequence of alternative splicing is relatively 
better understood. Alternative splicing is regulated by several factors including splice-site 
sequence, cis-regulatory sequences in the pre-mRNA, and expression of RNA-binding 
proteins and splicing factors. Splicing can result in changes in mRNA stability, 
localization, or reading-frame/translation affecting protein function137. Fibronectin (FN1) 
is one of the earliest genes identified to have alternatively spliced isoforms (e.g. notably 
cellular and plasma FN1) with functional consequences. With the advent of deep 
sequencing, more FN1 isoforms were discovered in different developmental context.  
In VSMCs, alternative splicing plays a large role in phenotype modulation. In 
synthetic/de-differentiated VSMCs, the RNA-binding protein, polypyrimidine tract binding 
protein (PTBP1), is upregulated, which results in exon exclusion from several  
differentiated VSMCs genes138. Another RNA-binding protein, Quaking (QKI) is 
upregulated in human neointimal injury and in synthetic VSMCs. QKI promotes the 
expression of a Myocardin isoform that is pro-proliferative, while in differentiated 
VSMCs, QKI is low and a pro-contractile Myocardin isoform is expressed139. A global 
analysis VSMC splicing also showed that genes in contractile/differentiated VSMCs tend 
to have more intron-retention and “poison exons” resulting in pre-mature stop codons138. 
As alternative splicing appears to regulate VSMCs during phenotypic modulation and in 
neointimal lesions, which are characteristically stiffer81,93, we hypothesize that matrix 
stiffness alters alternative splicing events through differential regulation of splicing 
factors and RNA-binding proteins. Indeed, in a gene-specific manner, a recent study 
identified that matrix stiffness regulated alternative splicing of fibronectin in endothelial 
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cells73. In contrast, I will approach this question using an unbiased survey of the VSMC 
transcriptome in response to stiffness. 
Bioinformatic pipelines for characterizing transcriptome landscapes 
Although next-generation sequencing technology has been able to produce data even 
more rapidly, the number of predictive tools and knowledge-databases lag behind. For 
example, unlike protein coding genes, lncRNAs do not possess conserved protein 
coding domains with which we can predict their biological and cellular function. 
Nevertheless, several strategies have been employed to analyze large datasets and 
characterize global transcriptome properties or identify specific candidate targets.  
Machine-learning: Principal component analysis and hierarchical clustering 
In this context, machine learning broadly refers to unbiased statistical methods to find 
characteristics and insights in data. Although “machine learning” has become a buzz-
phrase in the last few years due to the explosion of big data, it is conceptually old and 
encompasses familiar methods such as linear regression as well as new, more complex 
techniques. The two most common machine-learning techniques used with 
transcriptome level data are principal component analysis (PCA) and hierarchical 
clustering. 
 
PCA aims to condense high-dimensionality (>50,000 genes per sample) of 
transcriptome-wide data into several “principal components”. Instead of plotting a 
50,000-dimensional plot (where each axis represents one gene) which cannot be 
visualized, PCA aims to represent the variation of those 50,000 dimensions in only 2 or 3 
dimensions which can be easily visualized in a traditional plot (where each axis is a 
principal component). These principal components (which mathematically are 
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eigenvectors) are derived to represent the maximal variations in gene expression. Each 
principal component is uncorrelated to all other principal components, and typically, 2 - 3 
principal components encompass most of the variability in the data. Plotting samples on 
a PCA plot allows visual assessment of overall similarities and differences between 
samples, and whether the samples segregate into interesting groups. How samples 
segregate in a PCA plot is useful for visualizing what sample characteristics is 
associated with maximal gene expression variation140.  
 
Hierarchical clustering also allows us to take high-dimensionality gene expression data 
and determine “distances” between genes and/or samples, and mathematically define 
groups of genes/samples. Genes that behave similarly across all samples are “close in 
distance” and tend to group together, and samples whose transcriptomes behave 
similarly across all genes are clustered together141. 
Selecting Candidates and Predicting Function 
Methods to identify novel stiffness-mediated cellular processes and potential functional 
candidate genes include sequence and gene set enrichment, conservation analyses, 
and correlation analyses.  
 
In enrichment analyses, an entire transcriptome is searched for over-represented gene 
signatures, or, in other words, expression patterns that occur more likely than random. 
These signatures are sets of genes grouped by any characteristic. Commonly used 
grouping characteristics include genes that function in a common cellular process, share 
similar genomic positions, or respond to a common stimulus. This general method is 
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employed in this chapter and in subsequent chapters. Specifics about this method 
relevant to other chapters will be discussed in those sections. 
 
Sequence information obtained through RNA-sequencing also enables several analysis 
opportunities to identify novel transcriptome characteristics and responses, such as the 
identification of novel and unannotated genes, the identification of novel splicing patterns 
and transcripts, and conservation analyses. Conservation at the sequence and structural 
level is often a characteristic used as an indicator that an RNA or protein contains 
evolutionarily important functionality. Conservation as a predictive tool is particularly 
evident in that homologous protein domains often have similar functions. In part, 
microRNA conservation analyses also enabled the discovery of previously unknown 
microRNA genes, the prediction of their targets, and the understanding of their 
biogenesis. In comparison to protein coding genes and microRNAs, lncRNAs are 
significantly less conserved. However, several lncRNAs with conserved properties (e.g. 
sequence level, syntenic position, exon structure, tissue-specific expression) have been 
identified with cross-species functionality142. The lncRNAs discussed in the introduction 
of Chapter 3 and interrogated in Chapter 4 represent functionally conserved lncRNAs 
with sequence and positional conservation.  
 
Correlation analysis is also a particularly powerful tool in identifying networks of 
functional gene relationships.  Early analyses of microarray data utilized expression 
pattern correlations to identify sets of tightly co-expressed genes. Some sets were later 
experimentally determined to be regulated by common upstream mechanisms.  
This method can also be used to infer the function of an unknown gene from the known 
function of a highly-correlated gene143–146, and will be used for predicting lncRNA 
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function, described more in following chapter. Correlation analyses can prioritize 
potentially human disease-relevant genes from a longer list. For example, one approach 
is to use observations from genome-wide association studies (GWAS). GWAS discovers 
common human variants associated with human diseases and traits. Although GWAS 
does not prove a causal link between a variant and a disease, it is often inferred that 
genes near a GWAS variant (within the same haplotype-block) are functionally relevant 
in those diseases. Indeed, several efforts have demonstrated GWAS-identified variants 
to be functionally important in disease pathogenesis147. Thus, a list of candidate genes in 
VSMCs, for example, could be prioritized by selecting genes that are in proximity to 
GWAS-identified variants in vascular disease, as they may be significant in vascular 
disease processes. 
 
Lastly, all the outputs from these aforementioned analyses can feedback into larger 
machine-learning algorithms to improve predictive power. For example, multiple datasets 
have been incorporated into machine learning models to predict whether a lncRNA is a 
functional growth modifier. In this method, characteristics about experimentally-validated 
growth-modifying lncRNAs (e.g. specificity of expression, correlated expression to 
nearby coding genes, number of exons, proximity to disease SNPs, proximity to 
epigenetic marks) can be used to build a model that predicts whether an unknown 
lncRNA is likely to be a growth-modifying lncRNA or not127. 
Summary 
In this chapter, I define and characterize the stiffness-sensitive transcriptome in human 
aortic and coronary VSMCs. To achieve this, I performed deep RNA-sequencing of 
VSMCs grown on physiologically soft and pathologically stiff hydrogels matrices. I used 
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donor-matched aortic and coronary VSMCs such that observed differences in aortic and 
coronary VSMC expression are due to the VSMC-origin and not from a confounding 
donor-specific effect. This chapter establishes the similarities and differences in the 
transcriptome response of aortic and coronary VSMCs to matrix stiffness in gene 
expression, alternative splicing, and predicted functional consequences of transcriptome 
differences. 
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METHODS 
 
Cell Culture on Stiffness-tunable Hydrogels 
Donor-matched human primary aortic (Ao) and coronary (Co) artery smooth muscle cells 
were cultured with smooth muscle growth medium-2 (SmGM2, Lonza) with all 
supplements. Donor-matched primary VSMCs were used for the RNA-seq experiments. 
Primary and hTERT-immortalized Co VSMCs (XS12C1, Lonza) were also used for 
investigating MALAT1 and PACER biology in Chapter 3 and 4. VSMCs were serum-
starved for 48 hours in smooth muscle basal medium (SmBM, Lonza) supplemented 
with heat-inactivated fatty acid-free bovine serum albumin (1 mg/mL) before plating on 
hydrogels with SmGM2. 
 
Preparation of Polyacrylamide Hydrogels 
Physiologically soft (2-4 KPa) and pathologically stiff (20-25 KPa) hydrogel matrices 
coated with human fibronectin were fabricated as previously described148,149. These 
elastic moduli are comparable to those reported for human atherosclerotic lesions150 and 
have been shown previously to affect VSMC proliferation44,81. Furthermore, we used 
fibronectin as a vascular disease relevant cell adhesion matrix, as fibronectin expression 
is limited in normal healthy arteries but increased in disease such as 
atherosclerosis151,152. We prepared polyacrylamide hydrogels as previously 
described148,149. Briefly, acrylamide/bis-acrylamide solutions were polymerized on 
glutaraldehyde-functionalized coverslips at ratios 0.3%/7.5% for pathologically stiff (20 to 
25 KPa) and 0.03%/7.5% for physiologically soft (2 to 4 KPa) with acrylic acid N-
hydroxysuccinimide ester. Hydrogels were then functionalized with 5 µg/mL human 
fibronectin overnight and blocked with 1 mg/mL bovine serum albumin prior to cell 
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seeding. Hydrogels were made on coverslips of varying sizes (50-mm for the RNAseq 
study, 18-mm for validation, knockdown, and overexpression studies, and 12-mm for 
EdU incorporation and migration studies). 
 
RNA-sequencing and Bioinformatic Analysis 
Four sets (biological replicates) of serum-starved donor-matched Ao and Co VSMCs 
were plated at 10,000 cells/cm2 for 24 hours on 50-mm soft and stiff hydrogels (4 
samples per set, total 16 samples). Cells were seeded at 10,000 cells/cm2, a relatively 
low density, to minimize cell-cell interactions such that transcriptional changes resulted 
primarily from cell-ECM stiffness interactions. Total RNA was isolated from cells using 
RNeasy Mini Kit (QIAGEN) and TRIzol reagent following the manufacturer’s instructions. 
Ribosomal RNA was depleted using Illumina Ribo-Zero Gold, and libraries were 
prepared using a strand-specific TruSeq RNA library Prep kit (Illumina). Samples were 
then sequenced on a HiSeq2500, 100bp paired-end (Illumina). Reads were mapped 
against hg19 using STAR153. Alignment files were then filtered for high quality reads 
(score >= 30) and sorted using SAMtools154. Counts per gene were determined using 
HTSeq155 and human GENCODE v19 annotations118. Normalization for expression and 
differential expression were done using DESeq2156. Stiffness-sensitive genes were 
defined based on a false-discovery rate cut-off < 1% for each Ao and Co VSMCs. For 
conservation, tissue-specificity, pathway, and correlation analyses, stiffness-sensitive 
genes were determined by combining Ao and Co VSMC data with a false-discovery rate 
cut-off < 1%. 
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These data have been deposited in NCBI's Gene Expression Omnibus and are 
accessible through GEO Series accession number GSE100081 
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE100081). 
 
Expression Analysis and Transcriptome-level Clustering 
We defined a gene to be expressed in cultured Ao and Co VSMCs if the average 
number of normalized counts determined by DESeq2 was greater than 8. We also 
assessed expression cut offs of up to 100-200 normalized counts and found similar 
qualitative findings between Ao VSMCs and Co VSMCs. To assess gene expression in 
whole human coronary and aortic tissues, we used expression data from GTEx 
(downloaded from the GTEx portal, gtexportal.org). An RPKM > 0.7 cut off was used to 
classify a gene as being expressed in each tissue type. 
 
We defined lncRNAs as genes annotated in GENCODE with the following 
transcript_type terms: lincRNA, antisense, processed_transcript, sense_intronic, and 
sense_overlapping. 
 
Principal component analysis and hierarchical clustering were performed in R using the 
top 500 variant genes among all RNA-seq samples. Euclidean distances were used for 
complete-linkage hierarchical clustering. Top variant genes were determined by 
calculating the expression variance of each gene across all samples (Ao and Co VSMCs 
cultured on both soft and stiff). Heatmaps were generated in R using the pheatmap 
package. Venn diagrams were generated in R using the VennDiagrams package. 
 
Conservation and Tissue Specificity Analysis 
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To assess the sequence conservation of stiffness-sensitive v. insensitive genes, we 
used the pre-computer PhastCons 46-way (vertebrate) scores that were downloaded 
from the UCSC browser (http://genome.ucsc.edu/). Scores were calculated for each 
exon per gene accounting for the length of each exon. Cumulative distributions were 
determined and plotted for stiffness-sensitive and stiffness-insensitive genes. A 
Kolmogorov–Smirnov test was performed to determine statistical significance between 
distributions. 
 
For each stiffness-sensitive and insensitive gene identified in Ao and Co VSMCs, we 
counted the number of tissues where that gene had a median RPKM > 0.7 in the GTEx 
database. Cumulative distribution functions of the number of tissues expressing VSMC-
identified (in this study) stiffness-sensitive v. insensitive genes were generated. A 
Kolmogorov–Smirnov test was performed to determine statistical significance between 
these distributions. 
 
Pathway Analysis and Correlation Analysis 
Differential gene expression lists generated by DESeq2 using combined Ao and Co 
VSMC expression values were uploaded into Ingenuity Pathway Analysis (QIAGEN). A 
FDR < 1e-7 and an absolute LogFC > 1 were used to select analysis-ready molecules. 
Top enriched “categories” and “functions” were assessed. We identified lncRNAs 
attributed to each significant category or function. These enriched lncRNAs were then 
ranked based on the number of occurrences within the significant category or functions. 
 
KEGG and REACTOME terms were enriched using the Gene Set Enrichment Analysis 
tool (GSEA, Broad Institute)157. For each VSMC cell type, genes were ordered based on 
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their FDR values resulting from differential expression analysis (DESeq2). This ordered 
list was used as an input for GSEA. Significant term enrichment was determined using 
an FDR <1% for KEGG terms or PWER < 1% for REACTOME terms. 
 
To characterize the transcriptome landscape locally to each lncRNA, Spearman’s 
correlation coefficients and p-values were calculated for all pairs of genes within the 
same chromosomes using the combined Ao and Co VSMC expression data. We 
focused on all lncRNAs and plotted correlation scores vs. distance from the lncRNA in 
base pairs. To determine statistically significant correlated lncRNA-gene pairs, we 
corrected for multiple hypothesis testing (Bonferroni, e.g. p-value threshold for 
significance was p < 1e-5 for all lncRNA-gene pairs within 50kb from the lncRNA, plotted 
as red dots). Histogram plots of significant correlations were compared between 
stiffness-sensitive lncRNAs and an equivalent number of the most variant (calculated by 
variance across all Ao and Co VSMCs) stiffness-insensitive lncRNAs. 
 
To identify putative functional stiffness-sensitive lncRNA-protein coding gene pairs, we 
ranked the top stiffness-sensitive lncRNAs (fold change > 2) that were significantly 
correlated with a stiffness-sensitive protein coding gene (with fold change > 2) with an 
association p-value < 1e-3 and within 100kb away from each other. The top stiffness-
sensitive lncRNA-protein coding gene pairs are presented in Table 5. 
 
Differential Splicing Analysis using MAJIQ 
Fasta files and STAR-aligned files from the RNA-seq experiment were used as inputs 
into MAJIQ to quantify the PSI (percent spliced in), which is the relative abundance of 
each local splice variations (LSV, or splice junction) in each gene158. For each LSV, the 
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delta PSI (change in PSI between soft and stiff matrices) threshold cutoff was set at 20% 
(E(dPSI) > 0.2). MAJIQ and VOILA were run for Co VSMC and Ao VSMC separately.  
 
Association of Stiffness-sensitive Splicing to Cardiovascular GWAS traits. 
Differentially spliced genes as defined above were associated with SNP variants in the 
NHGRI-EBI GWAS Catalog (www.ebi.ac.uk/gwas) Version 1.0. The genomic coordinate 
for each SNP was translated into hg19 coordinates using the track: “GWAS catalog”, 
table: “gwasCatalog” from the UCSC genome table browser. Only SNPs relevant to 
vascular disease and genome-wide significant (p < 5 x10-8) were used for analysis. The 
list of relevant vascular diseases used in this analysis is in Appendix 1. Only genes 
within 50kB of the disease-associated SNP were considered as “associated” to stiffness-
sensitive genes. 
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RESULTS 
The Landscape of the Stiffness-sensitive Transcriptome of Co and Ao VSMCs 
(Gene Expression Level) 
We implemented deep RNA-sequencing to comprehensively define gene expression in 
donor-matched aortic (Ao) and coronary (Co) vascular smooth muscle cells (VSMCs) in 
response to physiologically soft and pathologically stiff hydrogel matrices (Figure 1).  
Using GENCODE annotations, we identified a total of 17,716 genes expressed in either 
Ao or Co VSMCs and in either soft or stiff conditions (Figure 2A); 93.2% were expressed 
in both cell lineages (DESeq2 mean normalized counts > 8). Of all expressed genes, 
13,574 were protein-coding genes, and 2,379 were long non-coding RNAs. Further 
inspection revealed protein-coding genes are more commonly expressed in both 
lineages of VSMCs than lncRNAs (95.7% v 82.9%). These proportions are consistent 
with expression data obtained from whole human coronary and aortic tissues in the 
GTEx database (Figure 3). The degree of uniquely expressed lncRNAs (17.1%) and 
protein coding genes (4.3%) may reflect the unique developmental origin and 
transcriptome program of Ao and Co VSMCs. 
 
Principal component analysis of the top 500 most variant genes revealed that matrix 
stiffness is a major contributor to expression differences (as is it most segregated by the 
first principal component) and accounts for approximately 54% of variation in gene 
expression. VSMC origin is also a major contributor accounting for about 36% of the 
expression variance (Figure 2B). Consistent with this analysis, unsupervised hierarchical 
clustering with the 500 most variant genes revealed that Ao and Co VSMCs cultured on 
the same matrix stiffness clustered together (Figure 2C). This clustering is similar when 
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clustering based only on protein coding genes or even lncRNAs despite their reduced 
overlap in expression between Ao and Co VSMCs (Figure 2D). 
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Figure 1. Experimental and computational flow chart for interrogating the VSMC stiffness-
mediated transcriptome. 
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Figure 2. Expression Landscape of Aortic and Coronary VSMCs 
(A) Venn Diagrams depicting the overlap of expressed genes (defined as normalized counts > 8) 
in Ao VSMCs and Co VSMCs by type. (B) Principal component analysis plot of the first two 
principal components using the top 500 variant genes (all genes). (C) Hierarchical clustering of all 
Ao and Co VSMC samples using the top 500 variant genes (all genes). (D) Principal component 
analysis and hierarchical clustering of all Ao and Co VSMC samples by either the top 500 variant 
protein coding genes or lncRNA genes 
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Figure 3. Expression Landscape of Whole Aortic and Coronary Artery Tissue from GTEx 
Database  
(A) Comparison of expression overlap of human aortic tissue and coronary artery tissue from 
GTEx. Venn diagrams depicting the overlap of expressed genes (defined as RPKM > 0.7) in 
aortic and coronary tissue expression data. 
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Global Characteristics of Stiffness-sensitive Gene Expression of lncRNAs and 
Protein-coding Genes  
We conducted pair-wise differential expression analysis and found that a total of 5818 
genes are differentially expressed by matrix stiffness (stiffness-sensitive, SS) in either 
Ao or Co VSMCs (FDR<1%) (Figure 4A,Figure 4B). From here on, we will define SS 
genes as the following: Origin-Specific (OS-SS) are genes identified as SS in only Ao 
OR Co VSMCs; Origin-Non-Specific (ONS-SS) are genes identified as SS in both Ao 
AND Co VSMCs; ALL-SS are genes identified as SS in either Ao OR Co VSMC (see 
Figure 4B for a graphical representation). 
 
Of the genes identified as stiffness-sensitive, 3098 (53.2%) are ONS-SS, with 2842 
being protein coding genes and 157 being lncRNAs. Interestingly, lncRNAs are more 
likely to be OS-SS than protein coding genes. That is, 57% (206/363) of ALL-SS 
lncRNAs are OS-SS, compared to only 45% (2377/5219) of ALL-SS protein coding 
genes are OS-SS (Figure 4C). 
 
We also found that if a gene was SS in either VSMC (ALL-SS), that gene was more 
likely to be expressed (DESeq2 normalized count > 8) in both VSMC lineages than a 
gene that was stiffness-insensitive (Figure 5). For example, 93% of ALL-SS lncRNAS 
are expressed in both VSMCs and 88% of OS-SS lncRNAs are expressed in both 
VSMCs. This is in comparison to stiffness-insensitive lncRNAs, where only 83% of 
stiffness-insensitive lncRNAs are expressed in both VSMCs. This is similar, but to a 
lesser degree, for protein coding genes. 98% of ALL-SS protein-coding genes are 
expressed in both VSMCs and 97% of OS-SS protein coding genes are expressed in 
both VSMCs, while 96% of stiffness insensitive protein coding genes are expressed in 
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both VSMCs (Figure 5A, Figure 5B).  We also analyzed these percentages over different 
DESeq2 count thresholds (used to define if a gene was expressed) and found that these 
qualitative findings hold true across a large range of cut-off values (Figure 5C). Taken 
together, these observations suggest that genes classified as SS tend to be expressed 
in an origin non-specific manner (found to be expressed in both VSMCs), and that the 
SS transcriptome may be conserved. Conversely stated, stiffness-insensitive genes 
were more likely to be expressed in an VSMC-origin specific manner. 
 
Indeed, we find that SS genes were significantly more conserved at sequence level 
using phastCons scores (Figure 6, Left). SS protein coding genes and lncRNAs both 
exhibited increased conservation over stiffness-insensitive genes. Furthermore, using 
data from the GTEx project, we find that SS genes are expressed (cutoff of RPKM>0.7) 
in more tissue types than stiffness-insensitive genes (Figure 6, Right). The SS 
transcriptome appears to be a conserved cellular response, which suggests that SS 
lncRNAs, by way of their increased conservation across species and tissue-types, may 
control stiffness-dependent functions. 
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Figure 4. Heatmap of the VSMC Stiffness-sensitive Gene Expression 
(A) Heatmap of stiffness-sensitive genes (FDR < 0.01) in both Co VSMC and Ao VSMCs. 
Heatmap colors correspond to log2 (normalized counts). (B) Legend for diagram of origin-specific 
stiffness-sensitive genes (OS-SS), origin-non-specific stiffness-sensitive genes (ONS-SS), or 
stiffness-sensitive genes in either Ao or Co VSMCs (ALL-SS). (C) Venn diagrams depicting the 
overlap in stiffness-sensitive genes in Ao and Co VSMCs. 
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Figure 5. Cell-specific expression of stiffness-sensitive genes 
(A) Venn diagrams depicting the number of cell-specific stiffness-sensitive genes (by FDR<0.01) 
that are cell-specific-expressed (by normalized count > 8) or expressed in both Ao and Co 
VSMCs. (B) Overlap of expressed stiffness-sensitive genes (identified in either Ao or Co VSMCs) 
in Ao or Co VSMCs. 93% of ALL-SS lncRNAs (identified as stiffness-sensitive in either Ao or Co 
VSMCs) are expressed (normalized count > 8) in both Ao and Co VSMCs compared to 83% of 
stiffness-insensitive lncRNAs. More stiffness-sensitive genes are expressed in both cell types 
than stiffness-insensitive genes. (C) Percent overlap as in panel B but comparing stiffness-
sensitive vs. all genes per subtype over various expression cut-offs (DESeq2 normalized count 
from 0 – 200). 
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Figure 6. Sequence Conservation and Tissue Expression Analysis of the VSMC Stiffness-
Sensitive Genes 
Cumulative distributions of conservation (phastCons) scores and tissue expression (GTEx) of 
stiffness-sensitive v. stiffness-insensitive genes. In-set figure of lncRNA distribution shows 
zoomed-in distribution at conservation scores 0 to 0.15. A right-shifted cumulative distribution 
demonstrates higher conservation or expression in more tissues. P-values determined using a 
Kolmogorov–Smirnov test.  
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To identify putative stiffness-dependent functions common and unique to Aortic and 
Coronary VSMCs, we performed unbiased enrichment analyses using Gene Set 
Enrichment Analysis157 and Ingenuity Pathway Analysis (QIAGEN) (Figure 7). Both 
methods identified several highly enriched cellular processes in both Ao and Co VSMCs: 
cell cycle, growth, death, motility, morphology, RNA post-transcriptional modifications 
(such as splicing).   
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Figure 7. Predicted Stiffness-dependent cellular functions 
(A) Venn Diagrams representing the common and unique gene sets enriched from the KEGG and 
REACTOME databases. (B) Selected common KEGG and REACTOME pathways enriched in 
both Ao and Co VSMCs. The full list appears in the Appendix. (C) Top categorical pathways 
enriched in shared stiffness-sensitive genes in Ao and Co VSMCs using Ingenuity Pathway 
Analysis 
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The Landscape of the Stiffness-sensitive Splicing in Co and Ao VSMCs (Isoform 
Level) 
Another level of transcriptome diversity and regulation is alternative splicing events. 
Splicing was a highly predicted process regulated by stiffness in both Ao and Co VSMCs 
(Figure 5, Terms: KEGG-Spliceosome, Reactome-mRNA_Splicing, Ingenuity-RNA post-
transcriptional modifications). Within these gene sets were stiffness-sensitive RNA-
binding proteins and splicing factors such as PTBP1 (upregulated by stiffness (Ao, Co) 
log2FC (-0.55, -0.6), FDR (3e-3, 8e-4)), previously identified to regulate splicing in VSMC 
phenotypic modulation. To assess splicing events in response to stiffness, we used the 
MAJIQ (Modeling Alternative Junction Inclusion Quantification) algorithm suite158 to 
detect and quantify local splice variations (or splicing events). In contrast to stiffness-
sensitive gene expression, stiffness-sensitive splicing was less similar between Ao and 
Co VSMCs. Only 61 genes (12.8%) were differentially spliced in both Ao and Co VSMCs 
(Figure 8A). About one-third (23) of these 61 genes were also differentially expressed at 
the gene level in both VSMCs, while another one-third (23) of these genes were only 
differentially spliced without change in their gene-level expression (Figure 8B).  Thus, 
alternative splicing appears to be a more origin-specific layer of the stiffness-sensitive 
transcriptome than gene level expression.
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Figure 8. Stiffness-sensitive splicing in Co and Ao VSMCs 
(A) Venn Diagram depicting the number of genes differentially spliced by stiffness in Ao and Co 
VSMCs. A gene was considered differentially spliced by stiffness if that gene had a local splice 
variation (LSV or splice junction) with > 20% differential exon/intron inclusion (delta PSI). (B) 
Four-way Venn diagram comparing differentially expressed vs. differentially spliced genes in Ao 
and Co VSMCs. 
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Global properties of differentially spliced genes 
Using the Database for Annotation, Visualization and Integrated Discovery (DAVID) 
tool159,160, we looked for properties annotated to differentially spliced genes in both Ao 
and Co VSMCs. Table 1 depicts the list of enriched annotations and terms associated 
with differentially spliced genes. Surprisingly, a significant number of differentially spliced 
genes are annotated as “phosphoproteins” in the uniprot database (35 out of 61).  
Several terms are also associated to known mechanotransduction components: 
cytoskeleton and actin-binding proteins. Four genes containing SH3 domains were also 
enriched in this analysis (Table 2). SH3 domains (Src homology 3 domains) are protein 
domains often found in signal transduction proteins allowing for protein-protein 
interactions especially in cytoskeletal and small GTPase signaling pathways161,162. 
Whether these four genes and their SH3 domains are involved in stiffness-dependent 
downstream effects is unknown. 
Thus, we further analyzed how the differential splicing events in these four genes may 
alter their properties. Surprisingly, the stiffness-mediated splicing events in these four 
genes directly involved their SH3 domains (Figure 9). We found that matrix stiffness in 3 
out of 4 of these genes (SASH1, MACF1, and MIA3) increased the relative abundance 
of exon junctions consistent with transcripts lacking SH3 domains (Figure 9 A, B, D).  
And at the gene expression level, both MACF1 [(Ao,Co), log2FC (0.77, 0.9), FDR (9e-6, 
4e-6)] and MIA3 [(Ao,Co), log2FC (1.1, 1.3), FDR (9e-10, 2e-10)] were down-regulated 
by stiffness. In contrast, SH3PXD2A (Figure 9 B) had a more complex local splicing 
pattern with multiple acceptor exons and 1 common splice donor exon. For SH3PXD2A, 
stiffness increased the relative abundance of transcripts containing 3-4 SH3 domains 
(Figure 9 C, green junction), and decreased the relative abundance of a novel junction 
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not annotated in the GENCODE annotations (Figure 9 C, red junction). This novel 
junction is predicted to cause a frameshift and a premature stop codon resulting in a 
transcript with only 1 partial SH3 domain.  Taken together, stiffness alters the relative 
abundance of SH3 domains in transcripts of these 4 genes and may affect contribute to 
stiffness-mediate signal transduction.  
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Category Term Gene Count P-Value 
Benjamini 
Corrected p-Value 
UP_KEYWORDS Alternative splicing 43 0.000027 0.0037 
UP_KEYWORDS Phosphoprotein 35 0.00033 0.023 
UP_KEYWORDS Cytoplasm 23 0.0026 0.085 
UP_KEYWORDS Cytoskeleton 10 0.0023 0.1 
UP_KEYWORDS Acetylation 18 0.0042 0.11 
UP_KEYWORDS Actin-binding 5 0.0054 0.12 
UP_KEYWORDS Coiled coil 16 0.0081 0.15 
UP_KEYWORDS SH3 domain 4 0.018 0.27 
UP_KEYWORDS Glycolysis 2 0.077 0.57 
UP_KEYWORDS Isopeptide bond 7 0.07 0.6 
UP_KEYWORDS Tumor suppressor 3 0.076 0.6 
UP_KEYWORDS Nucleus 20 0.061 0.62 
UP_KEYWORDS Ubl conjugation 9 0.069 0.63 
UP_SEQ_FEATURE splice variant 36 0.000027 0.0083 
UP_SEQ_FEATURE compositionally biased region:Poly-Ser 6 0.01 0.65 
UP_SEQ_FEATURE compositionally biased region:Poly-Gln 4 0.0077 0.7 
UP_SEQ_FEATURE compositionally biased region:Pro-rich 7 0.04 0.96 
UP_SEQ_FEATURE short sequence motif:Nuclear localization signal 4 0.06 0.98 
UP_SEQ_FEATURE domain:SH3 3 0.076 0.98 
 
Table 1. Enriched annotations of differentially spliced genes 
Enriched uniprot terms associated with the 61 commonly differentially spliced genes in both Ao 
and Co VSMCs. Categories are derived from the uniprot database (uniprot.org). The number of 
genes associated to each term is denoted under “gene count”.  
 
Gene Symbol Gene Name 
MACF1 microtubule-actin crosslinking factor 1 
MIA3 MIA family member 3, ER export factor 
SASH1 SAM and SH3 domain containing 1 
SH3PXD2A SH3 and PX domains 2A 
 
Table 2. Differentially spliced genes with SH3 domains 
Genes associated with the uniprot term SH3 domain and are differentially spliced by stiffness in 
either Ao or Co VSMCs 
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Figure 9. Schematic diagrams of differentially spliced genes containing SH3 domains  
(Continued below)
47 
 
Figure 9 (Continued). MAJIQ Local Splice Variation (LSV) Diagrams depict the splicing junctions 
found to be stiffness-sensitive. The yellow square represents an exon that acts as the common 
splice acceptor/donor. Red, blue and green squares represent exons that act as the differentially 
included or excluded exon. The percent spliced in (PSI) is the relative abundance of each junction  
in the LSV. The horizontal bars represent the delta PSI of each junction on stiff or soft matrices. 
 
Below each LSV diagram is a track view of each gene’s structure from the GENCODE V19 
Comprehensive Set Track from UCSC Genome Browser. Each isoform and the exon-intron 
structure is represented in black. The dotted red line represents where an SH3 domain is 
encoded. Red, blue, green and yellow highlighted regions correspond to the same exon squares 
in the LSV diagram. Junctions are also depicted above the gene track.  
(A) Schematic for SASH1. The red junction, increased relative abundance by stiffness, represents 
an isoform lacking the SH3 domain.  
(B) Schematic for MACF1. The blue junction, increased relative abundance by stiffness, 
represents an isoform lacking the SH3 domain. 
(C) Schematic for SH3PXD2A. The green junction, increased relative abundance by stiffness, 
represents isoforms containing 4 entire predicted SH3 domains. The red junction, decreased in 
relative abundance by stiffness is not represented in any of the annotated isoforms and may be a 
novel junction. This junction would result in a premature stop codon resulting in a transcript 
containing 1 partial SH3 domain. 
(D) Schematic for MIA3. The blue junction, increased in relative abundance by stiffness 
represents an isoform lacking the SH3 domain. 
 
Association of stiffness-sensitive spliced genes with cardiovascular disease-
GWAS variants 
Several GWAS variants have been associated with alternative splice sites and events, 
termed splicing quantitative trait loci (splicing-QTL)163. We asked whether any of the 61 
commonly spliced genes were associated with GWAS variants of cardiovascular traits 
relevant to aortic disease, coronary disease, or vascular stiffening. Only 2 of the 61 
stiffness-spliced genes were associated with GWAS-identified loci: FURIN-FES and 
MIA3. Variants near FES and MIA3 were associated with coronary artery disease, 
myocardial infarction, and blood pressure.  
As described previously, the relative abundance of MIA3 containing SH3 domains is 
reduced by stiffness. Three disease-associated variants are found within the MIA3 gene; 
one variant (rs35700460) is located in the intron directly upstream of the isoform lacking 
the SH3 domain, and two (rs17465637 and rs67180937) are located further downstream 
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near constitutive exons (Figure 10 A). The risk-alleles for all three SNPs are eQTLs and 
associated with reduced MIA3 gene expression (in aortic but not coronary tissue), but 
none were splicing-QTLs in the GTEx database (Table 3). 
Two variants were also identified in the FURIN-FES locus (Figure 10 B). One variant 
(rs2521501) located in an intronic region of FES, was associated with blood pressure (a 
consequence and risk factor of vascular matrix stiffening). This variant was also 
identified in a myocardial infarction GWAS, but its p-value (2e-7) was just under the 
genome-wide significance threshold (p < 5e-8). The second variant (rs17514846) is 
located in an intronic region of FURIN and is associated with coronary artery disease but 
also with a p-value (3e-7) just under the genome-wide significance threshold. Whether 
both of these variants are linked to changes in FURIN and/or FES activity is unknown. 
The FES intronic variant (rs2521501) is an eQTL for FES, with the risk-allele associated 
with reduced expression (in aorta and tibial artery but not coronary tissue), but not a 
splicing-QTL in the GTEx database (Table 3). 
As FES was differentially spliced by stiffness and intronic variants in FES were 
associated with several cardiovascular traits, we further investigated the splicing pattern 
in FES. Surprisingly, matrix stiffness increased the relative abundance of exon junctions 
consistent with FES transcripts lacking an SH2 domain (Figure 10 B, blue junction). SH2 
(Src homology 2) domains, like SH3 domains, are critical in protein-protein interactions 
and signal transduction, but specifically allow binding to phosphorylated tyrosine 
residues161,162. Taken together, these observations suggest that stiffness-mediated 
splicing of FES and MIA3 could be a mechanism contributing to vascular-related 
diseases.  
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Gene Symbol SNP P-Value Effect Size Tissue 
MIA3 rs67180937 1.3E-06 -0.30 Artery - Aorta 
MIA3 rs35700460  3.9E-06 -0.28 Artery - Aorta 
MIA3 rs17465637  1.3E-06 -0.29 Artery - Aorta 
FES rs2521501  2.6E-10 -0.34 Artery - Aorta 
FES rs2521501 4.3E-08 -0.21 Artery - Tibial 
 
Table 3. Expression quantitative trait loci (eQTL) for cardiovascular disease-related GWAS 
variants associated with stiffness-sensitive genes.  
These data are from the GTEx (gtexportal.org) database. eQTLs were searched in aorta, 
coronary artery, and tibial artery tissues. Effect sizes < 0 correspond to reduced expression 
associated with the risk-allele. 
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Figure 10. Schematic diagrams of stiffness-sensitive spliced genes and relationship to 
cardiovascular trait GWAS-identified variants. 
(continued below) 
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Figure 10 (Continued). For each locus (A) and (B), the table of GWAS-identified variants (SNP) 
and the associated disease trait is listed. The reference for the discovery of each variant is listed: 
Wain LV
23
, Ehret GB
164
, Schunkert H
164
, Nikpay M
165
. The location and type of each variant is 
listed and depicted each schematic (green arrow). 
(A) Schematic for the MIA3 Locus. Table of the GWAS-identified traits in the MIA3 locus. The 
blue junction, increased in relative abundance by stiffness represents an isoform lacking the SH3 
domain. 
(B) Schematic for the FURIN-FES Locus. Table of the GWAS-identified traits in the FURIN-FES 
locus. The blue junction, increased in relative abundance by stiffness represents an isoform 
lacking the SH2 domain. 
 
DISCUSSION 
Although vascular stiffness has been identified as an important risk factor for 
cardiovascular disease, our understanding of how vascular stiffness alters vascular 
cellular behavior is incomplete. This study provides the first comprehensive analysis, at 
the gene-level and isoform-level, comparing the stiffness-sensitive transcriptome in 
human Ao and Co VSMCs with a focus on lncRNAs. We found that Ao and Co VSMC 
transcriptome profiles are significantly dictated by matrix stiffness, and that stiffness-
sensitive genes (whether protein coding or lncRNA) are more commonly co-expressed in 
Ao and Co VSMCs compared to stiffness-insensitive genes. We also found that VSMC 
stiffness-sensitive genes are overall more species conserved and expressed in more 
tissue types than stiffness-insensitive genes. Furthermore, we observed that stiffness-
sensitive lncRNAs may be more origin-specific response (between Ao and Co VSMCs) 
than stiffness-sensitive protein coding genes.  
 
We find that ECM stiffness significantly dictates the transcriptomic identity of Ao and Co 
VSMCs. Prior studies have suggested that VSMC from different embryologic origins are 
rather phenotypically stable even when transplanted into disparate vascular 
microenvironments98,110,111; however, these transplantation studies are uncontrolled for 
any particular microenvironmental parameter. By using donor-matched Ao and Co 
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VSMCs, any differences we observe in the transcriptome of Ao and Co VSMCs arise 
from contributions from embryologic lineage programs or the effect of ECM stiffness. Our 
clustering analysis suggests that ECM stiffness may override the embryologic-origin 
contributions to the transcriptome; the transcriptome of Co VSMCs/stiff matrix is more 
similar to Ao VSMCs/stiff matrix than Co VSMCs/soft matrix. However, we also did 
identify the presence of OS-SS genes and observed that SS lncRNAs tended to be more 
origin-specific than SS protein coding genes. 
 
Several studies support this notion that ECM stiffness may significantly dictate cell 
transcriptomic identity. ECM stiffness and other mechanical parameters are critical in 
tissue and organ development166. Early studies demonstrated that ECM stiffness can 
dictate stem cell fate and that different stiffness can promote different lineages167–170. 
ECM stiffness has also been shown to alter nuclear mechanics, chromatin organization 
and the activity of a variety of ubiquitous transcription factors in multiple cell types, 
leading to global transcription changes56,60,171–173.  
 
In further support of this idea, we found that ALL-SS (identified as stiffness-sensitive in 
either Ao or Co VSMCs) tended to be expressed in both VSMC lineages and across 
more tissue types than stiffness-insensitive genes. These stiffness-sensitive genes were 
also more conserved across species at the sequence level. This suggests that the 
stiffness-sensitive gene set may represent a critical response module across many cell 
types and regulate cell-ubiquitous processes, as predicted by enrichment analyses.  
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Implications of Splicing Observations 
At the transcript/isoform-specific level, we found that many splicing regulatory genes 
were stiffness-sensitive and an unbiased analysis of junctional reads altered by stiffness 
yielded many potentially stiffness-sensitive splicing events. We found that the stiffness-
sensitive splicing was highly origin-specific with only a 13% overlap compared to 
stiffness-sensitive gene level expression (53% overlap). 
The splicing of cytoskeletal proteins is a significant process in development and disease 
of cardiac, skeletal, and smooth muscle tissues137. Rather unsurprisingly, we found that 
cytoskeletal and cytoskeletal associated proteins were enriched in stiffness-spliced 
genes identified in both Ao and Co VSMC. However, rather unexpectedly, we found that 
SH3 domain containing genes were also enriched, and that the stiffness-sensitive 
splicing events are predicted to result in inclusion or exclusion of these domains. Though 
not shown above, several SH3 domain containing genes were also significantly spliced 
by stiffness in a VSMC origin-specific manner. RT-PCR analyses will be required to 
validate these RNA-seq findings. 
There is evidence that SH3 domains are important in VSMC-specific stiffness-sensing. 
For example, the SH3 domain in p130Cas, a key mechanotransduction protein, is 
necessary for transducing matrix stiffness into VSMC proliferation and intracellular 
stiffening93. As stiffness-dependent activation of p130Cas is phosphorylation-mediated, 
we did not necessarily expect nor find stiffness-mediated splicing of p130Cas. However, 
we inspected each of the SH3 domain containing genes and found that stiffness is 
predicted to repress inclusion of the SH3 domain in 3 genes (SASH1, MACF1, and 
MIA3) and include multiple SH3 domains in 1 gene (SH3PXD2A).  
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MIA3 (melanoma inhibitor activity member 3, a.k.a. TANGO1) is an endoplasmic 
reticulum resident transmembrane protein that functions in the packaging and export of 
several collagens (I, II, III, IV, VII, and IX), but not fibronectin, within large vesicles. The 
SH3 domain in MIA3 binds directly to collagen VII alpha-1 but not collagen I, despite 
global defects in collagen I deposition in MIA3-knockout mice174,175. Three intronic SNPs 
within MIA3 are associated with increased risk for coronary artery disease and 
myocardial infarction. How these SNPs contribute to this increased risk is unknown. 
However, each SNP is a significant eQTL for MIA3 gene expression in aortic but not 
coronary tissues (GTEx database). The risk-alleles for all three SNPs are associated 
with reduced MIA3 expression. We also found that stiffness reduced MIA3 gene level 
expression, with a disproportionate reduction in SH3-containing MIA3 transcripts. One 
SNP (rs35700460) is located upstream to the alternative start exon of the SH3-lacking 
MIA3 isoform, and perhaps contributes to usage of an alternative promoter. Thus, we 
could speculate that arterial stiffening and MIA3 locus SNPs may additively contribute to 
CAD and MI by reducing MIA3 expression, resulting in an abnormal vascular ECM.  
Except for MIA3, the specific role and binding partners of the SH3 domain in the 
remaining 3 genes are relatively unknown, but their overall function may suggest their 
role in stiffness-sensing. MACF1 (Microtubule actin crosslinking factor 1 or a.k.a. ACF7) 
coordinates microtubule alignment along F-actin at focal adhesions. MACF1-knockout 
keratinocytes exhibited larger focal adhesions and impaired migration without changes in 
phosphorylated FAK, or levels of active RhoA, Rac1, and Cdc42176. Perhaps the SH3 
domain in MACF1 is important for its association with the actin cytoskeleton and may 
partially control stiffness-mediated migration. 
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SH3PXD2A (SH3 and PX domains 2A, a.k.a. TKS5, Tyr kinase substrate with five SH3 
domains), is a critical and specific podosome/invadopodia adaptor protein required for 
cell invasion177. Podosome/invadopodia formation is upregulated by ECM stiffness in 
breast epithelium178 and reports have found SH3PXD2A containing podosome in VSMCs 
in vitro and in vivo179. Perhaps the stiffness-mediated inclusion (soft substrate-
associated truncation) of SH3 domains in SH3PXD2A serves to increase invasiveness of 
VSMCs during vascular disease. Lastly, almost nothing is known about SASH1 (SAM 
and SH3 domain containing protein 1), other than its expression has been linked to 
smoking and atherosclerosis180.  
Lastly, we found matrix stiffness was predicted to splice out the SH2 domain of FES. 
FES is a non-receptor protein tyrosine kinase implicated in cytoskeletal dynamics 
associated with cell-cell and cell-matrix adhesions181. It interacts with many signaling 
proteins implicated in mechanotransduction including p130Cas182. Whether FES plays a 
direct role in mechanotransduction is unknown, but the stiffness-mediated loss of an 
SH2 domain could significantly the activity of FES and its role in cytoskeletal signaling. 
Similar to MIA3, variants in FES were associated with vascular disease and are eQTLs 
with the risk-allele associated with reduced FES expression.  
Thus, in comparison to rapid phosphorylation/enzymatic activities attributed to SH2/SH3-
domain proteins, stiffness-mediated splicing of these domains may represent another 
layer of signaling regulation that occurs at a slower, transcriptional rate. Ultimately, 
whether these SH3 and SH2 domains are important in transducing the stiffness signal 
into VSMC functions will require further investigation using splicing blocking 
oligonucleotides and other molecular manipulations.  
56 
 
There are still many questions that can be asked of this data set. Specifically, in the 
context of splicing, motif analysis of the splice sites could yield insight into the specific 
splicing factors mediating stiffness-sensitive splicing. Indeed, motif analysis of 
differentially included exons in contractile vs. synthetic mouse VSMCs led to the 
identification of PTBP1138. In our dataset, PTBP1 was differentially expressed by 
stiffness, but surprisingly, none of the PTBP1 target VSMC genes were differentially 
spliced (not shown). Of note, QKI, a regulator of myocardin splicing that is upregulated in 
neointimal VSMCs, was not differentially expressed by stiffness.  As briefly mentioned in 
Chapter 1, matrix stiffness induced phosphorylation of an SR-splicing factor, leading to 
alternative splicing of fibronectin. Whether SR proteins are activated by phosphorylation 
in VSMCs could not be predicted using the RNA-seq data, but may be a potential 
mechanism for the observed stiffness-mediated splicing events. 
Our lab recently has performed RNA-sequencing of mouse VSMCs on varying stiffness 
substrates.  Although there will be differences in the mouse v. human transcriptome 
regulation at this complexity level, a comparison of stiffness-dependent splicing events in 
this mouse VSMC dataset with our human VSMC dataset may identify conserved events 
and splice-site sequences to help curate which isoforms are likely to be functional183, 
especially in the case of the predicted SH3 and SH2 splicing events. 
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CHAPTER 3: REGULATORS OF THE STIFFNESS SENSITIVE TRANSCRIPTOME 
Introduction 
Chapter 1 gave an overview of various types of transcriptional regulators in 
mechanosensing. This section will now specifically address two classes, transcription 
factors and lncRNAs, and how several were historically identified and predicted to 
function. 
Mechanosensitive Transcription Factors 
Several methods have been employed to find regulators of mechanotransduction. In 
general, the methods rely on finding patterns (known and unknown) that occur more 
likely than chance. 
In one approach, significance of overlap is tested between the set of all observed 
differentially expressed genes and the set of genes known to be regulated by a 
transcription factor (gene expression signature). This is done over all known transcription 
factors. Those signatures with significant overlaps are likely to explain a part of the 
stimulus-mediated differential expression. This is the method employed by ingenuity 
pathway analysis(QIAGEN) and DAVID159 bioinformatics tools. This approach was used 
in part by the authors who identified YAP/TAZ as mechanosensitive transcription factors. 
In combination with historical empirical evidence that suggested YAP/TAZ would be 
stiffness-sensitive, they tested several in-house curated gene signatures for significant 
overlap and found only YAP/TAZ to be significant68.  
Another approach termed gene set enrichment analysis (GSEA) is a method developed 
by the Broad Institute and utilizes an array of gene signatures, not limited to those 
modulated by transcription factors, but also containing common transcription factor 
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motifs, genes on common chromosomes, genes in a common curated cellular process 
(e.g. KEGG, REACTOME), genes associated with specific cancers, mutant cells, and 
genes in response to pharmaceutical compounds. Instead of an overlap, GSEA 
compares a rank-ordered list of differentially expressed genes (often by some statistic, 
either fold change or p-value). It then determines which gene signatures in its entire 
database are over-represented at each end of the differential expression list by 
calculating an enrichment score and empirically determining the p-value for significance. 
This method was used to help identify a PRC2 signature in mechanosensing60. 
Lastly, motif searching in promoters of differentially expressed genes is an unbiased 
approach that searches for common over-represented DNA sequences. These 
sequences are then matched with known DNA-binding motifs. This method is especially 
useful for sets of genes that have been poorly studied and therefore has no known 
signature, such as the thousands of newly identified lncRNAs, and can be done in a 
targeted way with one gene or a set of genes. This general method of promoter 
searching was used to identify RARG (retinoic acid receptor-G) as a stiffness-dependent 
regulator of Lamin A expression171. 
However, there are limitations to these methods. For example, in motif searching, while 
a transcription factor binding motif may be enriched upstream of a set of genes, it is not 
guaranteed that that transcription factor is active and occupying those regions. Similarly, 
in gene expression signature enrichment, an enriched gene signature for factor A could 
be explained by another factor(s) that also redundantly activate factor A-target genes 
(i.e. multiple factors can activate the same gene). Thus, this could lead to false positives 
in the enrichment process, especially if factor A is not expressed in the cell of interest 
and other factors generate a factor A-like signature. 
59 
 
Cell/Context Specific Transcription Factors 
By extension, there may be cell-specific mechanosensitive transcription factors. As 
described in Chapter 1, mechanotransduction events often require an intact contractile, 
cytoskeletal network for force propagation, generation and signaling (e.g. RhoGTPases). 
It would then be reasonable to suspect that transcription factors that interact with these 
machineries would be stiffness-sensitive, but this is not necessarily the case. For 
example, in the enrichment analyses that identified YAP/TAZ, several other 
transcriptional regulators (e.g. SRF/MAL, NF-kB, and TGF-β/SMAD) were not enriched 
despite their known dependence on cytoskeletal changes and mechanical stimuli68. 
Indeed, there are cell/tissue-specific mechanosensitive transcription factors, such as 
NKX2.5184, whose expression is mostly restricted to cardiac tissues (GTEx). And there 
are relatively ubiquitous mechanosensitive transcription factors, like the aforementioned 
YAP/TAZ173 and also RARG, which controls Lamin-A expression and scales with 
stiffness over many human and mouse tissue171. But even these ubiquitous factors can 
have differential effects based on their interacting partners. For example, YAP may 
differentially interact with its DNA-binding partners (e.g. TEADs, TBX5, SMADs, RUNX2) 
in different situations to activate gene programs185–187. Thus, while many common 
pathways exist during mechanotransduction, different cells and different context of 
stimuli may utilize different transcriptional regulators. 
The Role of lncRNAs as Transcriptional Regulators 
As mentioned in the introduction to Chapter 2, lncRNAs do not possess coding domains 
as in protein coding genes, limiting our abilities to predict their function. By combining 
multiple layers of data from high-throughput sequencing (e.g. RNA-seq, ChIP-seq, 
Chromatin-conformation-capture, CHART and ChIRP-seq, RIP-seq, etc) and 
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bioinformatics analyses, several roles of lncRNAs and mechanism of function have been 
identified. By and large, the primarily elucidated function of lncRNAs is to regulate gene 
expression, examples which will be discussed below. 
Correlation analyses between lncRNAs and nearby coding genes is a commonly used 
approach to predict lncRNA function at a whole transcriptome level because of its early 
relative “success” (in quotations because how much failure is attributed to this strategy is 
rarely reported) in identifying lncRNA function. This “guilt by association” strategy was 
derived from noticing that lncRNAs and nearby protein coding genes were highly 
correlated, and by using known functions of nearby coding genes, the function of an 
unknown lncRNA could be roughly predicted126,188–190.  
For example, the identification and elucidation of function for lincRNA-p21 resulted from 
the observation that many lncRNAs were associated to p53 regulated genes. One of 
those lncRNAs, lincRNA-p21, was found to be a direct target gene of p53 and 
subsequent experiments determined that lincRNA-p21 mediates p53-induced apoptosis 
by binding with hnRNP-K, a ribonucleoprotein, to repress transcription of survival 
genes191.  
Long non-coding RNAs: Mechanisms of action 
Over time, more studies identified more lncRNAs that regulated gene expression, not 
only of nearby genes, but also of distant genes within the same and even on other 
chromosomes. This section discusses some of these mechanisms. 
In one mode, lncRNAs can associate with chromatin modifying complexes to repress 
expression of target genes. The lncRNA, HOTAIR was found to regulate gene 
expression at hundreds of sites by binding with PRC2, a polycomb repressor complex 
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protein189,192. XIST is another lncRNA that binds PRC2, and it is transcribed from one X-
chromosome to transcriptionally silence the entire second X-chromosome in females to 
control gene dosage. One study also found that ~20% of expressed lncRNAs were 
bound to PRC2, and that silencing of select lncRNAs led to upregulation of genes known 
to be PRC2 targets193. Other complexes known to associate with lncRNAs include 
DNMT3b and CTCF: pRNA, a lncRNA that associates with DNMT3b to mediate DNA 
methylation, and SRA, a lncRNA that binds CTCF to enhance its function to insulate 
genomic regions194,195. As discussed in Chapter 1, one study showed that cyclic stretch-
mediated gene repression acts through PRC2 (in a cytoskeletal tension and 
emerin/LINC complex dependent manner)60. Thus, it is within reason to suspect that 
specific “mechanosensitive” lncRNAs may guide PRC2 to mechanosensitive coding 
gene loci.  
As there are many lncRNAs transcribed in relative proximity to protein coding genes, 
often in enhancer regions and at low abundance, it has been proposed that some of 
these lncRNAs may represent non-functional by-products of local transcriptional 
processes (transcriptional noise). However, a critical early study demonstrated that 
lncRNA transcripts could have enhancer-like functions (enhancer RNAs). During 
keratinocyte differentiation, several lncRNAs were differentially expressed near coding 
genes that were known to be involved in differentiation. SiRNA silencing of several 
candidate lncRNAs were found to reduce expression of their neighboring coding genes, 
demonstrating that the lncRNA transcript was functional. A series of reporter constructs 
then demonstrated that it was specifically the lncRNA transcript that potentiated the 
promoter activity of its target protein coding gene196. 
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LncRNAs can act locally and globally. As discussed above, HOTAIR and XIST regulate 
expression in hundreds of sites by associating with PRC2. Some lncRNAs also remain 
locally anchored at their site of synthesis and enact their influence at distal genomic loci. 
For example,  HOXA locus genes, through chromosomal loops, are brought into the 
proximity of the lncRNA, HOTTIP197. Even multiple gene loci on separate chromosomes 
can be recruited to the lncRNA loci, as is in the case of Firre198.  
Another mode of transcriptional regulation by lncRNAs is through regulation of splicing. 
One mechanism was observed in NAT/Zeb2. NAT is a lncRNA that is transcribed from 
the anti-sense strand of the protein coding gene Zeb2. Successful splicing of Zeb2 
results in a transcript that is not normally translated, however, expression of NAT, which 
overlaps the 5’ splice-site, prevents splicing of Zeb2 leading to a translatable product199. 
Another was observed in the lncRNA, MALAT1, which regulates splicing by controlling 
the expression, localization and activation of SR family splicing factors200 
Lastly, lncRNAs have been described to act in the cytoplasm and regulate mRNA 
stability and translation. For example, they have been reported to act as miRNA 
sponges, or competing endogenous RNAs128,201. In this mode, the lncRNA transcript may 
contain sequences that can compete and effectively sequester microRNAs that would 
otherwise degrade a protein coding transcript. 
The long non-coding RNA, PACER 
Part of this chapter experimentally addresses the role of the lncRNA, PACER (p50-
associated COX-2 extragenic RNA), as a potential regulator of stiffness-mediated gene 
expression. We identified PACER in a transcriptome-wide correlation analysis as a 
stiffness-sensitive lncRNA whose expression is highly correlated to the nearby stiffness-
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sensitive coding gene, PTGS2 (shown later in the Results section). Our lab and others 
have previously found that PTGS2 is an important player in VSMC stiffness-sensing and 
vascular stiffening44,217, and thus we chose to investigate PACER as a potential 
upstream regulator of stiffness-mediated PTGS2 expression in VSMCs.  
PACER is an 800 bp, single exon, polyadenylated lncRNA located ~200 bp upstream to 
PTGS2 and is transcribed in the antisense direction relative to PTGS2. As PACER is 
located in the known PTGS2 promoter region, its sequence overlaps several known 
DNA-binding sites for transcription factors (e.g. NF-κB, AP1, NF-IL6, CREB, 
TCF4/LEF1) known to functionally regulate PTGS2202,203. Nevertheless, PACER was 
shown not to be a transcriptional by-product at the PTGS2 promoter. In human breast 
epithelial cells and macrophages, PACER positively regulates PTGS2 expression by 
sequestering p50 NFkB from the PTGS2 promoter. P50 NFkB when homodimerized 
forms a repressive complex, but when heterodimerized with RelA/p65 NFkB (which 
contains a transactivating domain) can promote transcription203. Other lncRNAs have 
also been implicated in NFkB signaling, and also binding to NFkB affecting its ability to 
bind DNA204. Whether PACER is functional in VSMCs and regulates stiffness-mediated 
PTGS2 expression is unknown and will be addressed in this chapter. 
 
METHODS 
 
Unbiased motif searching 
We searched predicted promoter and enhancer regions (determined by chromHMM/NIH 
roadmaps)205,206 in human heart/aorta within the regions 5kb upstream of the 
transcriptional start site and 1kb downstream of genes that were upregulated by stiffness 
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(combined Ao and Co VSMCs). Enriched motifs were identified using the MEME suite. 
Significant motifs were then matched to known transcription factor databases (JASPAR 
core vertebrates v.2014207, Uniprobe207, and Jolma207) using TOMTOM208. Motifs with 
known matches were then filtered, keeping matches with e-values < 1, which represents 
the number of false positives expected at that point in the rank of matches per motif. We 
further curated the remaining matched transcription factors for those with known 
documented roles in VSMCs. 
Immunofluorescence and quantification of TBX5/YAP localization 
hTERT-immortalized Co VSMCs were serum starved for 48 hours then cultured on soft 
and stiff hydrogels for 24 hours in SmGm-2 (Lonza). Cells were fixed in 4% 
paraformaldehyde for 20 minutes at room temperature, permeabilized in PBS containing 
0.5% Triton X-100, 0.11g/mL sucrose, and 0.61 mg/mL MgCl2. Cells were blocked with 
1%BSA in PBS for 30 minutes. YAP antibody (mouse monoclonal IgG2a, sc-101199, 
Santa Cruz) was used at 0.5 ug/mL (1:200 dilution) and incubated overnight at at 4ºC, in 
1% BSA in PBS. TBX5 antibody (rabbit polyclonal) was obtained as a gift from Cathy 
Hatcher (Philadelphia College of Osteopathic Medicine, PCOM, Philadelphia PA) and 
previously described207. Primary incubation for TBX5 was at 0.26 ug/mL overnight at 
4ºC, in 1% BSA in PBS. Alexa-488 or Alexa-568 conjugated secondary antibodies (Life 
Technologies) to mouse or rabbit were used at 1:200 at room temperature for 1 hour. 
Hydrogels were mounted with ProLong® Gold antifade reagent with DAPI (nuclear stain) 
overnight before imaging. 
An epifluorescence microscope with a 20X objective was used to image YAP, TBX5 and 
DAPI signals. The area normalized intensity of TBX5 and YAP in both the nucleus and 
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cytoplasm was determined using FIJI imaging software207: nuclear area delineated by 
the DAPI signal, total cellular area by the boundary of each cell in the phase channel, 
cytoplasmic area determined as the total cell area minus the nuclear area. The 
nuclear/cytoplasmic ratio reported is the area-normalized intensity of the 
nucleus/cytoplasm per cell. Approximately 20 cells were counted per experiment per 
stiffness over four experiments (n = 4). Per experiment, the average nuclear/cytoplasmic 
ratio of cells grown on stiff substrates are normalized to ratios from soft substrates which 
was set to 1. 
The correlation between YAP and TAZ localization determined using the 
nuclear/cytoplasmic ratio per cell over all experiments (n = 148). Reported is the 
spearman’s correlation coefficient calculated using the Hmisc library in R. 
Gene Expression Validation by Quantitative RT-PCR 
RNA was extracted from VSMCs using TRIzol reagent according to the manufacture’s 
protocol and reverse transcribed using the High-Capacity cDNA Reverse Transcription 
Kit (Life Technologies). cDNA was subjected to quantitative PCR with the following 
primer-probe sets from Life Technologies: PTGS2 (Hs00153133_m1). To assay for 
PACER expression, we obtained a Custom Plus Taqman Assay (Assay ID: AJWR2Q9, 
Life Technologies). The primer-probe set used for 18S rRNA has been previously 
described148 . Real-time qPCR results were calculated using the ddCT method with 18S 
rRNA as the reference. 
 
Assessing LncRNA Knockdown 
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LncRNA knockdown was performed using locked nucleic acid GapmeRs (Exiqon). 
Primary and hTERT-immortalized Co VSMCs were transfected with Lipofectamine 
RNAiMAX according to the manufacturer’s protocol (Life Technologies) and with 
GapmeRs targeting either a negative scramble control (50nM) or PACER (50nM) for 48 
hours in Opti-MEM (Life Technologies) in 6-well plates before cells were trypsinized, 
centrifuged, and replated on 18-mm hydrogels with SmGM2. Sequences for the 
GapmeRs are as follows: Negative Control (5'-AACACGCTATAACGC-3'), PACER-ASO-
1 (5'-TTAGCGTCCCTGCAAA-3'), PACER-ASO-2 (5'-GAACTTTAAAACTCGA-3'), and 
PACER-ASO-3 (5’-TGCTTAGGACCAGTAT-3’). Degree of knockdown was assessed by 
quantitative RT-PCR. 
 
Western Blot for NFkB 
Serum-starved (48 hours) hTERT-immortalized Co VSMC were grown on soft and stiff 
hydrogels for 24 hours in SmGm-2 (Lonza) before being washed in PBS and lysed using 
the NE-PER nuclear and cytoplasmic extraction kit (Thermo Fisher). Cells on tissue-
culture plastic were treated with 25ng/µL TNF-alpha for 30 minutes as a control (Abcam, 
ab9642). Nuclear fractions were separated via the NuPage SDS Page system 
(Invitrogen, NP0322BOX). Primary antibodies used were anti-p65 NFkB (1:500, sc-372, 
Santa Cruz), anti-Lamin B (1:1000, sc-365214, Santa Cruz). HRP-conjugated anti-rabbit 
(1:2500, GE Healthcare Life Sciences, NA934V and NA931V) and Luminata Crescendo 
Western HRP substrate (Millipore, WBLUR0100) were used to visualize the signal. 
Inhibition of NFkB with BAY-11-7085 
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Serum-starved (48 hours) hTERT-immortalized Co VSMC were pre-incubated with either 
0.3 µM BAY-11-7085 compound (Cayman chemical, 14795) or equivalent volume of 
DMSO for 30 minutes prior to trypsin treatment of cells. Cells were subsequently seeded 
on soft and stiff hydrogels in the presence of either 0.3 µM BAY-11-7085 or DMSO for 
24 hours in SmGm-2 before RNA was collected. 
Statistical Analyses 
Statistical tests for each experiment are included in the figure legends. Briefly, student’s 
paired t-tests and two-way ANOVA were used in general for comparison between soft 
and stiff conditions with additional perturbations. For transcriptome-wide correlation 
analyses, p-values were calculated using the Hmisc library in R and the threshold for 
significance was Bonferroni corrected per condition. 
 
RESULTS 
Unbiased Motif Analysis Identifies TBX5 as a novel stiffness-sensitive 
transcription factor 
Several approaches exist to identify transcriptional regulators that may contribute to the 
observed transcriptome response to stimuli. We first chose to use unbiased motif 
analysis of genes differentially expressed by stiffness. We searched for recurring motif 
sequences in the promoter regions of these genes that had histone marks consistent 
with active promoters or enhancers. These statistically recurring sequences were then 
matched to known transcription factor motif databases and curated for transcription 
factors with documented activity in VSMCs. The resulting transcription factors are listed 
in Table 4. Among these factors, TBX5, a t-box transcription factor, was also identified in 
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Ingenuity pathway analysis as a potential upstream regulator of the stiffness-sensitive 
transcriptome (fisher’s exact test, p = 2.1e-4, Appendix 2). 
We further focused on TBX5 in Co VSMCs as its expression is restricted to the lungs 
and heart including the coronary arteries, but not the aorta, and is critical in coronary 
artery smooth muscle cell development207,209–213. Indeed, TBX5 expression in our RNA-
seq was ~10-fold lower in Ao VSMC than in Co VSMCs (Figure 11A). Data from another 
RNA-seq study in our lab also showed that TBX5 was further restricted to Co VSMCs 
and is not expressed in Co endothelial cells (not shown). TBX5 has also been shown to 
interact directly with the mechanosensitive YAP/TAZ186,214. Thus, we hypothesized that 
TBX5 may be a stiffness-sensitive transcription factor in Co VSMCs that may interact 
with YAP to regulate stiffness-mediated gene expression.   
To determine if the nuclear/cytoplasmic localization of TBX5 was stiffness-dependent, 
we cultured Co VSMCs on soft and stiff hydrogels and quantified TBX5 and YAP 
subcellular localization using immunofluorescence methods as shown by others68,170,171. 
Indeed, we find that nuclear localization of TBX5 was significantly increased on stiff 
substrates. YAP trended toward higher nuclear localization on stiff substrates (p = 0.053, 
Figure 11 B, D). YAP and TBX5 localization signals were also significantly correlated 
(spearman coefficient = 0.69, Figure 11C,D), consistent with studies showing direct 
interaction of YAP and TBX5 to activate their gene targets186,214. YAP/TBX5 gene targets 
(BIRC5 and BCL2L1) and YAP/TEAD gene targets (ANKRD1 and CTGF) were also 
increased on stiff substrates (Figure 11E). Taken together, these data suggest that 
TBX5 is a stiffness-dependent transcriptional regulator in Co VSMCs and may interact 
with YAP to drive stiffness-dependent gene expression.  
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Table 4. VSMC-relevant transcription factor motifs enriched in stiffness-sensitive 
genes using MEME/TOMTOM Suite 
This table includes the top motifs that were (1) enriched in predicted promoters and 
enhancers of stiffness-sensitive genes, (2) matched to known transcription factor motif 
sequences, and (3) were documented to have VSMC specific functions.  
Motif e-value. Statistical significance of the motif (e.g. the expected number of motifs one 
would expect to find in random sequences of similar size to the input search set). 
Match p-value. The probability that the match occurred by random chance according to 
the null model.  
Match e-value. The expected number of false positives in matches up this this point. 
Match q-value.  The minimum false discovery rate required to include the match.  
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Figure 11. Stiffness-dependent localization of TBX5 and YAP. 
(continued below) 
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Figure 11. Stiffness-dependent localization of TBX5 and YAP (continued) 
(A) Heatmap of the expression of TBX5 in Co and Ao VSMCs from RNA-seq 
(B) Ratio of nuclear intensity (area normalized) vs. cytoplasmic intensity (area normalized) of 
TBX5 and YAP in coronary VSMCs grown on stiff and soft polyacrylamide hydrogels. 
Nuclear/Cytoplasmic intensity ratios were normalized to those on soft hydrogels. Significance was 
determined using student’s paired t-test (* p < 0.05, $ p =0.053). Error bars are standard errors of 
the mean, data was generated from measuring 148 cells (87 Stiff, 61 Soft) over n = 4 different 
sets of soft and stiff hydrogels). 
(C) The nuclear/cytoplasmic ratio (area normalized) per cell (n = 148) for TBX5 and YAP are 
plotted on a scatterplot. TBX5 and YAP localization correlation was tested using a spearman 
correlation test.  
(D) Representative images of TBX5 and YAP immunofluorescence images of Co VSMCs used 
for panels (A) and (B). Scale bar = 50um 
(E) Expression of YAP/TBX5 and YAP/TEAD gene targets in Co VSMCs grown on soft and stiff 
from the RNA-seq dataset. Y-axis per subplot are DESeq2 normalized expression values. Log2 
Fold change and false discovery rate is reported for each gene target. 
 
 
Transcriptome-wide correlation analysis reveals coordinated expression of 
stiffness-sensitive lncRNA and stiffness-sensitive protein coding gene pairs 
LncRNAs and their neighboring genes are often correlated in their expression, and 
several studies have demonstrated that some lncRNAs regulate the expression of 
neighboring coding genes through various mechanisms127,129,215. We asked whether the 
VSMCs transcriptome-wide stiffness response may result in part by lncRNA regulation of 
nearby genes. Thus, we conducted transcriptome-wide correlation analyses between all 
lncRNA-gene pairs within the same chromosome. We found that the frequency of 
significantly correlated lncRNA-gene pairs increased based on the proximity of the 
lncRNA-gene pair (Figure 12). These significant correlations were also predominantly 
positive. When comparing stiffness-sensitive to insensitive lncRNAs, stiffness-sensitive 
lncRNAs exhibited a greater number of correlated gene-pairs than stiffness-insensitive 
genes (Figure 13).  
 
The top 20 most highly correlated stiffness-sensitive lncRNA-protein coding gene pairs 
are presented in Table 5. The full list of significant correlations is presented in Appendix 
72 
 
6. Notably, we find that the lncRNA, RP5-973M2.2 (PACER) is highly associated with 
the stiffness-sensitive coding gene, PTGS2. PACER has been shown to positively 
regulate PTGS2 expression in several cell types203,216, and we and others have shown 
that PTGS2 is important in stiffness-sensing and contributes to vascular stiffening44,217. 
Furthermore, several lncRNAs are significantly correlated to matrix and cytoskeletal 
proteins that may potentially be involved in VSMC stiffness-sensing. EDIL3 (Del-1) is an 
extracellular matrix protein that regulates VSMC adhesion, migration, and 
proliferation218. Two nuclear membrane associated proteins are also highly correlated to 
stiffness-sensitive lncRNAs. SYNE3 (aka Nesprin-3), a component of the LINC (linker of 
the nucleoskeleton and cytoskeleton) complex which transmits mechanical stress from 
cytoskeleton to the nucleus, may be important in the stiffness-mediated transcriptional 
response61,219–221. TMPO (a.k.a lamin-associated polypeptide 2-alpha, LAP2α) is a LEM-
domain containing nuclear membrane protein which binds Lamin A, much like Emerin, a 
critical regulator of nuclear mechanotransduction64,222,223. 
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Figure 12. Increased lncRNA-gene pair correlation with pair proximity.  
(Continued below)  
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Figure 12 (Continued). Correlation distributions of the top variant 1000 lncRNAs expressed Ao and Co VSMCs over different distances (A) 
Scatter plot of all lncRNA-gene pair correlation scores. Each dot position represents the distance between a lncRNA and nearby gene (x-axis) and 
the Spearman’s correlation coefficient (y-axis). All possible lncRNA-gene pairs within the same chromosome were correlation tested and all 
lncRNAs are centered at the 0-position on the x-axis. Color of each dot represents significance after correction for multiple-hypothesis testing 
(black dots are insignificant, red dots are correlations with p < 1e-5). (B) Histogram depicting the distance distribution of significantly correlated 
lncRNA-gene pairs. (C) Histogram depicting the distance distribution of all correlation tested lncRNA-gene pairs. (D) Normalized distributions of 
significantly correlated lncRNA-gene pairs. The number of significant lncRNA-gene pairs per bin (distance from lncRNA) is normalized by the 
number of total lncRNA-gene pairs within that bin. 
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Figure 13. Increased lncRNA-gene pair correlation with pair proximity and stiffness-sensitivity.  
(Continued Below) 
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Figure 13 (Continued). Correlation distributions of all expressed Ao and Co VSMCs lncRNAs (first column), combined Ao and Co VSMCs 
stiffness-sensitive lncRNAs (second column), stiffness-insensitive lncRNAs (third column). (A) Scatter plot of all lncRNA-gene pair correlation 
scores. Each dot position represents the distance between a lncRNA and nearby gene (x-axis, within a +/- 50kb range) and the Spearman’s 
correlation coefficient (y-axis). All possible lncRNA-gene pairs within the same chromosome were correlation tested and all lncRNAs are centered 
at the 0-position on the x-axis. Color of each dot represents significance after correction for multiple-hypothesis testing (black dots are 
insignificant, red dots are correlations with p < 1e-5 for all lncRNAs, p < 4e-5 for stiffness-sensitive lncRNAs, p < 2e-5 for stiffness-insensitive 
lncRNAs). (B) Histogram depicting the distance distribution of significantly correlated lncRNA-gene pairs. (C) Histogram depicting the distance 
distribution of all correlation tested lncRNA-gene pairs. (D) Normalized distributions of significantly correlated lncRNA-gene pairs. The number of 
significant lncRNA-gene pairs per bin (distance from lncRNA) is normalized by the number of total lncRNA-gene pairs within that bin. 
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Top correlated stiffness-sensitive lncRNA-protein coding gene pairs 
 
LncRNA Log2 FC 
Distance 
(kB) 
PCG Log2 FC 
Spearman 
R 
Correlation 
p-value 
LINC00341 1.41 -65.7 SYNE3 1.00 0.98 4.00E-11 
RP11-54O7.1 1.05 -13.4 SAMD11 1.06 0.95 1.20E-08 
AC002116.7 -1.66 -40.4 WDR62 -2.17 0.95 2.70E-08 
RP11-800A3.4 2.85 20.7 P2RY2 2.26 0.94 3.90E-08 
TMPO-AS1 -1.97 0.9 TMPO -1.72 0.94 3.90E-08 
RP11-401P9.4 2.32 97.5 NKD1 2.06 0.94 7.80E-08 
RP11-386G11.10 -1.97 -61 TUBA1C -2.21 0.94 1.10E-07 
CTD-2269F5.1 1.17 -0.4 EDIL3 1.64 0.93 1.90E-07 
CTB-92J24.2 -1.61 12.9 ZNF726 -1.73 0.92 4.30E-07 
CTD-2298J14.2 1.37 -2.7 LRFN5 1.98 0.92 4.30E-07 
JHDM1D-AS1 1.66 0.2 JHDM1D 1.62 0.92 4.30E-07 
RP11-303E16.2 -1.5 24.3 CENPN -1.56 0.91 8.80E-07 
RP11-110I1.12 -1.03 -97.5 H2AFX -2.11 0.90 1.70E-06 
RP5-973M2.2 (PACER) 1.61 0.2 PTGS2 2.23 0.90 1.70E-06 
RP11-386G11.10 -1.97 -3.6 TUBA1B -2.01 0.90 2.10E-06 
RP3-462E2.3 1.78 45.9 ALDH2 1.08 0.90 2.50E-06 
AC009133.12 1.18 30.5 KIF22 -1.94 -0.89 3.60E-06 
CASC15 1.63 71 SOX4 1.74 0.89 5.10E-06 
RP1-151F17.2 1.4 2.9 ATXN1 1.08 0.89 5.10E-06 
 
Table 5. Top correlated stiffness-sensitive lncRNA-protein coding gene pairs.  
The top significantly correlated stiffness-sensitive lncRNAs-stiffness-sensitive protein coding gene 
pairs are listed. Protein coding genes and lncRNA genes are listed along with their log2 fold 
change (log2FC > 0 represents decreased expression by stiffness). The distance between gene 
pairs, Spearman’s correlation coefficient, and p-value are listed. The PACER-PTGS2 correlation 
is bolded. 
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Interrogation of the lncRNA, PACER as a potential regulator of nearby stiffness-
sensitive protein coding genes 
We further focused on the PACER-PTGS2 pair because of the importance of PTGS2 in 
ECM stiffening. Studies by our lab and others have previously suggested that PTGS2 is 
involved in a positive feedback stiffening mechanism whereby stiffness-mediated 
suppression of PTGS2 results in enhanced collagen and fibronectin production in 
VSMCs and fibroblasts leading to further ECM stiffening44,95. However, how matrix 
stiffness modules PTGS2 expression is unknown. PTGS2 is a known target gene of 
several transcription factors in response to several stimuli224. Recent studies in 
macrophages, mammary epithelial cells, and osteosarcoma cells show that PACER 
positively regulates PTGS2 expression via NFkB203,216, suggesting that the PACER-
PTGS2 correlation in VSMCs may underlie a functional link. NF-kB family members and 
pathways were also enriched as potential transcriptional regulators of the stiffness-
sensitive transcriptome (GSEA Figure 16A, pathway analysis fisher’s exact test p = 2.4e-
6). Specifically, RelA/p65 activity was also predicted to be inhibited by stiffness (z-score 
= 2.9, fisher’s exact test p = 2.4e-3, Appendix 2). Thus, we hypothesized that stiffness 
may act through PACER and NFkB to regulate stiffness-dependent PTGS2 expression 
and perhaps other stiffness-sensitive protein coding genes. 
 
We first expanded our correlation analysis of PACER with stiffness-sensitive protein 
coding genes within 1Mb. We also found that PLA2G4A, which codes for cytosolic 
phospholipase A2, is also correlated to PACER expression and is stiffness-sensitive in 
both Ao and Co VSMCs (Figure 14A, B). Interestingly, both PLA2G4A and PTGS2, 
which are located directly in cis to PACER, are key enzymes in arachidonic acid 
metabolism and the synthesis of prostacyclin, which regulates stiffness-dependent ECM 
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production44,45. RT-PCR confirmed that increased ECM stiffness reduced both PACER 
and PTGS2 expression in primary Ao and Co VSMCs (Figure 14C).  
 
To test whether PACER might coordinately regulate the expression of these nearby 
protein coding genes, we knocked-down and over-expressed PACER in hTERT-
immortalized Co VSMCs. We used three different LNA-GapmeR ASO (anti-sense 
oligonucleotides) to reduce PACER expression levels grown on soft matrices to that as 
in stiff matrices, but this reduction in PACER did not significantly alter PTGS2 or 
PLA2G4A expression (Figure 15A). Although knockdown with PACER-ASO-2 appeared 
to significantly increase expression of PLA2G4A, this may be an off-target effect as the 
other two ASOs targeting PACER did not alter PLA2G4A levels. We next used a 
lentiviral-based expression system (pSLIK225), to overexpress PACER. A diagram of the 
expression system is in Figure 15C. Consistent with the PACER-knockdown findings, 
overexpression of PACER in Co VSMCs both on soft and stiff matrices did not 
significantly change PTGS2 expression (Figure 15B). However, PLA2G4A expression 
was significantly higher only in VSMCs on soft substrates with PACER overexpression.   
 
We next interrogated the role of NFkB in stiffness-mediate PACER and PTGS2 
expression, as NF-kB was previously implicated in PACER-mediated regulation of 
PTGS2203. Pathway analyses predict that p65/NFkB pathways are activated by soft 
hydrogels, consistent with the increase in PTGS2 on soft hydrogels (Figure 14C). 
Indeed, the localization of p65 (RelA), the trans-activating subunit of NFkB is stiffness-
dependent. However, nuclear localization of p65 is increased on stiff hydrogels 
compared to soft hydrogels (Figure 16B). This suggests that increased PTGS2 
expression on soft hydrogels is independent of p65 NFkB activation. Furthermore, 
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inhibition of NFkB signaling using BAY-11-7085 also did not affect PTGS2 expression on 
soft hydrogels (Figure 16C). Taken together, these findings demonstrate that the 
PACER-NFkB-PTGS2 axis, while discovered in epithelial cells and macrophages, may 
not be intact in VSMCs.  
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Figure 14. Coordinate stiffness-sensitive expression of PACER, PTGS2, and PLA2G4A  
(A) UCSC Browser track view of PTGS2-PACER-PLA2G4A and their corresponding correlation in 
expression (from RNAseq) with Spearman’s correlation coefficient and p-value from donor-
matched Ao and Co VSMCs grown on soft and stiff hydrogels. (B) PACER (RP5-973M2.2), 
PTGS2 and PLA2G4A RNA-seq expression from donor-matched Ao and Co VSMCs. Log2FC 
and FDR are reported above each gene (C) PACER and PTGS2 expression by quantitative-RT-
PCR in (Left) primary Ao VSMCs (n = 5, **** p < 0.0001) and (Right) in primary Co VSMCs (n = 7, 
**** p < 0.0001). Two-way ANOVA, Holm-Sidak’s multiple comparison test. 
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Figure 15. Regulation of PTGS2 and PLA2G4A by PACER 
(A) PACER, PTGS2 and PLA2G4A expression by quantitative RT-PCR after PACER knockdown 
using 3 different LNA-GapmeRs in hTERT-immortalized Co VSMCs cultured on soft and stiff 
hydrogels (n = 4, * p < 0.05, ** p < 0.005, *** p < 0.0005, **** p < 0.0001, ns not-significant, Two-
way ANOVA, Holm-Sidak’s multiple comparison test).  
(B) PACER, PTGS2 and PLA2G4A expression by quantitative RT-PCR after lentiviral-based 
overexpression of PACER in hTERT-immortalized Co VSMCs grown on soft and stiff hydrogels (n 
= 4, **** p< 0.0001, Two-way ANOVA; Holm-Sidak's multiple comparisons test).  
(C) Vector map of the lentivirus-based system to overexpress PACER in VSMCs. Shown is the 
region between the two LTRs.  
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Figure 16. The role of NFkB in stiffness-sensitive PACER-PTGS2 expression. 
(A) Enrichment Score Plot for NFKB pathways using GSEA using RNA-seq of Ao and Co VSMCs 
cultured on soft and stiff hydrogels. (Left) Enrichment for NFKB using the transcription factor motif 
database, C3 (Right) Enrichment for TNFalpha signaling via NFKB using the hallmark database, 
H. 
(B) Western blot analysis for p65 NFkB in the nuclear fraction of hTERT-immortalized Co VSMCs 
grown on soft hydrogels, stiff hydrogels or tissue-culture plastic. TNF-alpha was added at 
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25ng/mL for 30 minutes prior to protein collection. Lamin B was used as an internal load control. 
Boxed in lanes represent different nitrocellulose membranes.  
(C) RT-qPCR expression of PACER and PTGS2 from hTERT-immortalized Co VSMCs cultured 
on soft and stiff hydrogels incubated with 0.3uM BAY-11-7085 for 24 hours. Student’s t-test was 
performed (n =5, *** p < 0.005, ns not-significant) 
 
DISCUSSION 
In this chapter, we used several different bioinformatics approaches to identify TBX5 and 
PACER as putative transcriptional regulators of matrix stiffness in VSMCs.  
TBX5 
Our results suggest that TBX5, as it is not expressed in Ao VSMCs, may be a Co 
VSMC-specific stiffness-sensitive transcription factor. We demonstrated that TBX5 
nuclear localization in Co VSMCs was increased by stiffness and highly correlated to 
YAP localization, a previously identified TBX5-binding partner186,214. We also showed 
that known YAP-TBX5 gene targets were up-regulated by stiffness in Co VSMCs, 
consistent with the localization data. These findings only suggest a potential role for 
TBX5. Further experiments in manipulating of TBX5 expression and TBX5-ChIP-qPCR 
to verify promoter occupancy will be needed. 
Several studies suggest potential mechanisms for how stiffness may localize TBX5. In a 
series of chick model studies, TBX5 was found to bind directly to LMP4, a PDZ-LIM 
domain protein that binds directly to F-actin. LMP4 has been shown to repress TBX5 
activity, and in its absence, TBX5 becomes predominantly nuclear226–228. This suggests 
stiffness-mediated TBX5 localization could be due to changes in the actin cytoskeleton.  
Stiffness-mediated TBX5 localization in our human Co VSMCs may also be related to 
changes in VSMC differentiation state. In the developing chick heart, TBX5 localization 
is spatially and temporally dynamic. In undifferentiated epicardial cells (the precursor to 
85 
 
coronary VSMCs that proliferate and migrate), TBX5 is predominantly nuclear. In 
differentiated epicardial cells (which express VSMC differentiation markers like 
calponin), TBX5 was both nuclear and cytoplasmic226. And in developed chick coronary 
artery sections, TBX5 was reportedly exclusively cytoplasmic228. Perhaps, human Co 
VSMCs in part become more synthetic/dedifferentiated consistent with their increased 
proliferative and migratory capacity on stiff matrices (shown in Chapter 4, and prior 
literature81,89). 
We further suspect that TBX5 may regulate stiffness-mediated cell responses such as 
proliferation/survival and migration in part through partnering with YAP, a key regulator 
of growth control. In humans, mutations in TBX5 result in Holt-Oram Syndrome, which is 
characterized by aplastic upper-limb malformations, congenital heart abnormalities, and 
coronary artery defects213,229,230. TBX5 mutations known to cause Holt-Oram Syndrome 
lead to reduced YAP/TBX5 association and reduced TBX5 transcriptional activity in 
cardiomyocytes214. Furthermore, a TBX5-YAP-β-catenin complex, but not TEAD-YAP, 
drives expression of BIRC5 and BCL2L1, though this study was done in cancer cells186. 
We find that stiffness increases expression of BIRC5 and BCL2L1 consistent with 
increased TBX5-YAP localization, but we also see increased TEAD-YAP targets, 
ANKRD1 and CTGF. Whether stiffness requires TBX5 and YAP in VSMCs to induce 
BIRC5/BCL2L1 expression will require further studies. Evidence in mice suggests that 
TBX5 may control VSMC proliferation and migration. TBX5-knockout mice exhibit poor 
coronary vasculogenesis, resulting from reduced epicardical cell proliferation and 
migration into the myocardium212. As TBX5 has been predominantly interrogated in 
either developing chicks and mice, or cancer cell models, whether TBX5 in mature 
human Co VSMCs still control these processes will require further work.  
86 
 
Transcriptome-wide Correlation 
In this study, we found that SS lncRNAs were significantly correlated with more of their 
nearby genes when compared to stiffness-insensitive lncRNAs, suggesting that SS 
lncRNAs may coordinate the stiffness-mediate protein coding response. We identified 
several highly correlated pairs that were within 100kB of each other listed in Table 5. 
Many of the protein coding genes in this list code for nucleoskeletal structures, and they, 
along with their correlated lncRNA, could play a role in mechanotransduction. Only two 
of the lncRNAs in this list have been previously studied, CASC15 and RP5-973M2.2 
(PACER), and both have been shown to regulate coding gene expression231. However, 
some of these lncRNA-coding gene pairs may be associated due to stiffness-driven local 
chromosome changes, whereby clusters of genes are simultaneously co-expressed. 
Thus, some of these lncRNAs may be non-functional and transcriptional noise, while 
others may represent true cis-regulatory functional lncRNAs.  
PACER 
We hypothesized that PACER may regulate two coding genes, PTGS2 and PLA2G4A. 
This was based on the highly correlated lncRNA-coding gene expression patterns, 
common coding gene function in arachidonic acid/prostacyclin metabolism, and prior 
reports of a cis-regulatory role of PACER on PTGS2 in three different human cell types 
(mammary epithelial, macrophages, osteosarcoma lines)203,216. However, it appears that 
this PACER-PTGS2 axis may not be present in human VSMCs and/or during stiffness-
sensing.  
 
This may be due to our findings that stiffness-mediated regulation of PTGS2 is NFkB-
independent, while PACER regulation is NFkB-dependent. We observed that PTGS2 
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expression was upregulated on soft matrices, and this effect was not reversed by 
inhibition of NFkB with BAY-11-7085 (BAY-11-7085 is an inhibitor of IκBα-
phosphorylation, which when phosphorylated releases NFkB to become active). 
Furthermore, the transactivating p65 NFkB subunit was predominantly nuclear on stiff 
substrates, as seen in other studies70,232,233. Given these findings, it makes sense that 
manipulation of PACER, and thus NFkB, would not have an effect on stiffness-regulated 
PTGS2 expression. 
 
Nevertheless, PACER may still have a stiffness-dependent and NFkB-dependent role by 
its previously reported role in sequestering p50 NFkB. As nuclear p65 was increased by 
stiffness, perhaps the simultaneous reduction in PACER may lead to less sequestered 
p50, and thus influence the p50/p65 NFkB balance. It is possible that this leads to global 
expression changes in stiffness-dependent NFkB gene targets (identified in our 
enrichment analyses) because PACER, unlike several locally acting lncRNAs, is not 
restricted to its site of transcription (~25% of its transcripts are cytoplasmic in 
macrophages)203.  
 
However, we also acknowledge that PACER’s function may be cell-type specific and 
non-functional in VSMCs, despite it being expressed and stiffness-dependent. This 
concept was demonstrated in a library-based lncRNA knockdown study over seven 
different cell lines which identified lncRNAs that were ubiquitously expressed, but 
functional in only 1 of 7 cell types127. There is also the possibility that the PACER-PTGS2 
axis may be present in primary VSMCs (where the correlation analyses identified 
PACER-PTGS2) and absent in hTERT-immortalized coronary VSMCs (where all the 
pathway interrogation experiments were conducted). We think this is unlikely as the 
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expression of PACER and PTGS2 are stiffness-dependent in both primary and hTERT-
immortalized VSMCs. Thus, an RNA-seq following manipulation of PACER on soft and 
stiff conditions will determine whether PACER has no function or have global 
transcriptional consequences. 
 
Then how does stiffness-regulate PTGS2? Many other transcription factor binding sites 
(e.g. AP1, NF-IL6, CREB, TCF4/LEF1) are upstream (-2kb) of PTGS2 and overlap 
PACER203,234, and several of these factors have been shown to regulate PTGS2 
expression in human VSMCs in response to various stimuli. Our enrichment analyses for 
potential upstream regulators of the stiffness-sensitive transcriptome also found CREB1 
(Ingenuity, fisher’s exact test p = 2.4e-11). However, more likely, at the time of this 
writing, a study showed that YAP/TAZ and TEAD mediated stiffness-repression of 
PTGS2 in pulmonary artery VSMCs96. They showed that both YAP and TAZ were 
sufficient and necessary for stiffness-dependent PTGS2 repression, and that this effect 
was TEAD-dependent (using TEAD-binding mutants of YAP and TAZ). Furthermore, 
stiffness-regulated YAP/TAZ localization is Rho-dependent, consistent with work in our 
lab showing that the stiffness-mediated PTGS2 response is also dependent on Rho 
activity94. 
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CHAPTER 4: MALAT1, a lncRNA regulator of stiffness-sensitive VSMC functions 
Introduction 
This chapter focuses on MALAT1, a lncRNA that was chosen as a candidate through an 
unbiased analysis of the stiffness-sensitive transcriptome in VSMCs. How MALAT1 was 
determined to be the focus of this chapter will be discussed in the results section, but 
this introduction serves to get the reader acquainted with the current knowledge about 
MALAT1, setting the context for the hypothesis generated. 
Discovery of MALAT1 
MALAT1 (metastasis-associated lung adenocarcinoma transcript-1, a.k.a. NEAT2, 
nuclear-enriched abundant transcript-2) was discovered in 2003, from a subtractive 
hybridization screen between primary human non-small cell lung cancer tumors that had 
metastasized vs. non-metastasized. MALAT1 was the most over-represented clone in 
this screen, and high MALAT1 expression was highly predictive for overall survival in 
lung adenocarcinomas, thus leading to its name235. Several years later, the mouse 
ortholog to MALAT1 was identified in mouse hepatocellular carcinoma236, and many 
reports have linked increased MALAT1 to a range of different human cancers: breast, 
renal cell, cervical, colorectal and bladder cancer 237. 
MALAT1 is a highly abundant, nuclear-retained transcript (hence its other name, 
NEAT2) that is ubiquitously expressed in many human tissues and highly conserved in 
mammals235,238. MALAT1 is a large transcript ~ 8000 bp long and can be processed into 
a long (~7000 bp), nuclear-retained segment (which is often referred to as the MALAT1 
transcript) and a short (61 bp), cytoplasmic segment (which is referred to as mascRNA, 
MALAT1-associated small cytoplasmic RNA)239. MALAT1 has a relatively long half-life (> 
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12 hrs) due to a triple helical structure on its 3’ end, compared to the ascRNA with half-
life < 6 hrs. Little is known about the role of mascRNA, and most studies to date have 
focused predominantly on MALAT1. 
Function of MALAT1: Proliferation, Migration, and Splicing 
The role of MALAT1 appears to be complex and perhaps cell and context-dependent. 
Key studies regarding the role of MALAT1 will be discussed below. 
Within the nucleus, MALAT1, through its two localization motifs, associate specifically 
with nuclear speckles, which are sites enriched with mRNA processing and splicing 
factors240. In HeLa cells, MALAT1 was found to regulate splicing programs and cell 
cycle, and in MALAT1 knockdown HeLa cells, SR splicing factors (SRSF1 and SRSF3) 
localization and activation were reduced leading to altered splicing in hundreds of 
genes200. Furthermore, in response to serum-stimulation, MALAT1 relocates and 
associates demethylated-pc2 (polycomb 2 protein, distinct from PRC2 mentioned in prior 
chapters) with growth control genes within the nuclear speckle. This pc2-MALAT1 
association promotes cell cycle progression by activating E2F1 and transcription of its 
targets241, and knockdown of MALAT1 results in aberrant cell cycle200,241. 
In contrast, one study used siRNA to knockdown MALAT1 in 10 different cell lines 
(mouse and human) and found proliferation defects in some cells lines but not others242. 
In zinc finger nuclease MALAT1 knockout A549s (human lung cancer cell), no difference 
in splicing compared to wild-type was found. No differential splicing was seen in the 
same candidate genes as those identified as differentially spliced in HeLa cells, nor in 
other selected candidates243. Instead, they found that MALAT1-knockout A549 cells had 
altered gene expression in metastasis-associated genes, resulting in functional defects 
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in migration and metastasis. A role for MALAT1 in migration has also been described in 
HUVECs, but the knockdown of MALAT1 resulted in increased migration along with 
reduced proliferation244. Lastly, these MALAT1-regulated proliferation, apoptosis, and 
migration effects have been observed in many different cancers as well245. Thus, 
MALAT1 appears to be critical for several cell functions in a cell specific manner. 
MALAT1 as a competitive endogenous RNA 
In addition to RNA processing within the nuclear speckle, MALAT1 has been proposed 
to act as a competitive endogenous RNA (ceRNA), as several microRNA seed 
sequences have been found in the long MALAT1 transcript. In human renal cell 
carcinoma, MALAT1 and miR205 interact to control E-cadherin expression246. In mouse 
myoblasts, MALAT1 coordinates with miR133 (to control SRF expression) and miR181a 
(to control MYOD activity) for myogenic differentiation247,248. Furthermore, MALAT1 has 
been shown to complex with Ago2249–251. These studies also suggest that MALAT1 may 
not just act as a “dummy” diversion/sponge. That is, the repression in MALAT1 by a 
diverted microRNA may contribute to cell phenotype as significantly as the concomitant 
increase in that microRNA’s mRNA targets. 
MALAT1 knockout Mice 
Given that significant phenotypes have been observed in proliferation, migration, splicing 
and differentiation, the in vivo role of MALAT1 was highly anticipated. At almost the 
same time, three separate labs generated their own MALAT1 knockout mice and 
surprisingly found no physiologic defects252–254. MALAT1 knockout mice breeding 
normal, and their offspring follow expected Mendelian ratios. There were no 
histopathological abnormalities assessed over 12 different organs. Staining for Ki67 
(proliferation) and caspases (apoptosis) were normal. Mouse embryonic fibroblasts 
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isolated from these knockouts had no altered nuclear speckle SR protein distribution or 
phosphorylation. No differential splicing was observed either in brain and liver tissues. 
HeLa cells were analyzed in parallel, and the aforementioned MALAT1-dependent HeLa 
phenotypes were reproduced252–254. Thus, it appeared that MALAT1 was dispensible for 
normal development and physiology in mice.  
Role for MALAT1 during pathology 
The finding that MALAT1 had no in vivo developmental phenotype was striking in 
comparison to the numerous in vitro and cancer observations. It was hypothesized that 
perhaps MALAT1 was important during pathological conditions, partially reconciling 
these seemingly discrepant observations. Indeed, MALAT1 had a phenotypic 
contribution in insult mouse models.  
In a cardiotoxin-induced skeletal muscle injury model, MALAT1-knockout mice had 
accelerated muscle regeneration after injury by increasing MYOD activity and myogenic 
differentiation255.  When MALAT1 was knocked-out in a MMTV-PyMT (mouse mammary 
tumor virus) mouse model, tumors were more cystic and differentiated compared to the 
solid and poorly defined tumors when MALAT1 was expressed. However, the number of 
tumors was not affected. The increased tumor differentiation was also associated with 
significantly fewer macro- and micro-metastasic lesions256. However, the loss of 
MALAT1 did not appear to be important in pressure-overload hypertrophic 
cardiomyopathy257 
In the vasculature, and as relevant to this chapter, MALAT1-knockdown using antisense 
oligonucleotides (ASO) in mice had reduced reperfusion after hind limb ischemia injury 
compared to control ASO. MALAT1 knockout mice also had statistically reduced 
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neonatal retinal vascularization, but the effect size was small. These finding were 
attributed to reduced proliferation and increased migration from MALAT1-knockdown in 
human umbilical vein endothelial cells244.  
These studies in the MALAT1 knockout mice support the notion that the presence of 
MALAT1 is functionally significant on pathologic backgrounds in vivo.  How these insults 
permit a role for MALAT1 is unknown, but we hypothesize that pathologic ECM stiffening 
plays a role in the function of MALAT1. Indeed, many tumors, especially mammary 
tumors, and hypoxic/ischemic-insults are characterized by increased ECM stiffening and 
post-injury fibrosis258–262. Furthermore, as MALAT1 and stiffness have been 
independently found to regulate proliferation and migration, they may be coordinating 
with one another to do so. Lastly, MALAT1 appears to have cell type-dependent effects, 
and while many cell types have been interrogated, the role of MALAT1 in VSMCs is 
unknown. Thus, this chapter focuses on how MALAT1 was chosen as a candidate gene 
representing the VSMC stiffness-sensitive response, and the role of MALAT1 in VSMCs 
and matrix stiffness. 
 
METHODS 
 
Identification of MALAT1 as a putative regulator of stiffness-dependent functions 
using Ingenuity Pathway Analysis 
We used Ingenuity pathway analysis (QIAGEN) to identify lncRNAs that may underlie 
the predicted functions from gene set enrichment analyses (Figure 7) because it relies 
on knowledge/literature-based annotations of lncRNA function. As described in Chapter 
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2, the differential gene expression lists generated by DESeq2 using combined Ao and 
Co VSMC expression values were uploaded into Ingenuity Pathway Analysis (QIAGEN). 
An FDR < 1e-7 and an absolute LogFC > 1 were used to select analysis-ready 
molecules. Top enriched “categories” and “functions” were assessed. We identified 
lncRNAs attributed to each significant category or function. These enriched lncRNAs 
were then ranked based on the number of occurrences within the significant category or 
functions. Only 3 lncRNAs were annotated in the ingenuity knowledge base for the 
enriched categories, and only 2 lncRNAs were annotated to enriched functions. 
Gene Expression Validation by Quantitative RT-PCR 
RNA was extracted from VSMCs using TRIzol reagent according to the manufacture’s 
protocol and reverse transcribed using the High-Capacity cDNA Reverse Transcription 
Kit (Life Technologies). cDNA was subjected to quantitative PCR with the following 
primer-probe sets from Life Technologies: MALAT1 (Hs00273907_s1), CCND1 
(Hs00765553_m1) and CCNA1 (Hs00171105_m1). The primer-probe set used for 18S 
rRNA has been previously described148 . Real-time qPCR results were calculated using 
the ddCT method with 18S rRNA as the reference. 
 
Assessing LncRNA Knockdown 
LncRNA knockdown was performed using locked nucleic acid GapmeRs (Exiqon). 
Primary and hTERT-immortalized Co VSMCs were transfected with Lipofectamine 
RNAiMAX according to the manufacturer’s protocol (Life Technologies) and with 
GapmeRs targeting either a negative scramble control (50nM) or MALAT1 (50nM) for 48 
hours in Opti-MEM (Life Technologies) in 6-well plates before cells were trypsinized, 
centrifuged, and replated on 18-mm hydrogels with SmGM2. Sequences for the 
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GapmeRs are as follows: Negative Control (5'-AACACGCTATAACGC-3'), MALAT1-
ASO-1 (5'-CGTTAACTAGGCTTTA-3'), MALAT1-ASO-2 (5'-ACTAGCGTGTGGAAAG-
3'). Degree of knockdown was assessed by quantitative RT-PCR. 
 
EdU Incorporation Assay 
Following knockdown with GapmeRs, primary or hTERT-immortalized Co VSMCs were 
plated at 10,000 cells/cm2 on 12-mm soft and stiff hydrogels in SmGM2 for 48 hours with 
10µM EdU (Life Technologies). Cells were fixed in 4% Paraformaldehyde overnight. EdU 
was visualized using the Click-iT EdU Imaging Kit (Life Technologies). Nuclei were 
stained with DAPI. Three fields of view were counted per hydrogel to determine the 
percent of EdU-positive cells relative to DAPI-stained cells. Relative EdU incorporation 
was determined by normalizing all conditions to the percent EdU of the control-GapmeR 
treated cells grown on soft hydrogels.  
 
Migration Assay 
For single cell migration studies, following GapmeR knockdown, Co VSMCs were plated 
at 5,000 cell/cm2 on 12-mm soft and stiff hydrogels overnight. NucBlue (Life 
Technologies) was then added (40µL per mL) with fresh SmGM2 30 minutes prior to the 
start of the migration study. Nuclei were then imaged using fluorescence every 5-10 
minutes for 5 hours. Three fields of view were captured per timepoint per condition. 
Nuclei were tracked using TrackMate (ImageJ). Nuclei that were not in the field of view 
for at least 4 hours were not counted. Median cell velocities, total distance (path-
dependent), and total displacement (path-independent distance) were calculated. 
Relative values for each parameter were determined by normalizing to the respective 
values on soft hydrogels with negative control GapmeR knockdown.  
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For the scratch wound assay, following GapmeR knockdown, hTERT-immortalized Co 
VSMCs were plated on 12-well plates in SmGM2 at 50,000 cells/cm2 overnight to 
achieve confluence. A uniform scratch was created using a 200µL pipet tip, cell debris 
was washed, and fresh SmGM2 was replaced. The wound closure was assessed by 
microscopy. 
 
RESULTS 
Identification of MALAT1 as a regulator of stiffness-dependent phenotypes 
Most lncRNAs have no known function, and none have been implicated in the response 
to ECM stiffening. To identify lncRNAs that may play a role in stiffness-mediated cellular 
responses, we used unbiased enrichment analyses (Ingenuity pathway analysis) and 
identified several highly enriched cellular processes in both Ao and Co VSMCs (Figure 
7C): cell cycle, growth, death, motility, morphology, and RNA post-transcriptional 
modifications. Among the ingenuity pathway categories and functions, MALAT1 was the 
most overrepresented lncRNA annotated to these functions (Table 6, Table 7). MALAT1, 
a highly conserved lncRNA, has been primarily implicated in cancer biology, and, more 
recently, in endothelial cell function. Whether MALAT1 plays a role in VSMCs or in 
stiffness-dependent functions is unknown. 
 
RT-PCR validated the RNA-seq finding that matrix stiffening reduces MALAT1 
expression in both Ao and Co VSMCs (Figure 17A, Figure 18A). We then focused on 
using primary and hTERT-immortalized Co VSMCs. Knockdown of MALAT1 with two 
different LNA-GapmeRs resulted in significant reduction in MALAT1 expression (Figure 
17B, Figure 18B). Upon MALAT1 knockdown, Co VSMCs lost their elongated cell 
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morphology (Figure 17C, Figure 18C).  MALAT1 knockdown also reduced stiffness-
dependent S-phase entry in Co VSMCs measured by EdU incorporation (Figure 17D, 
Figure 18D, Figure 19A) consistent with reduced cyclin D1 and cyclin A2 expression 
levels (Figure 19B). Reduced MALAT1 also decreased stiffness-induced Co VSMCs 
migration speed, total distance, and displacement (Figure 17E, Figure 18E), and slowed 
collective migration on a wound closure assay on stiff tissue culture plastic (Figure 19C). 
Taken together, these data show that MALAT1 is a positive regulator of VSMC 
proliferation and migration in response to ECM stiffness.  ECM stiffness negatively 
regulates MALAT1, and this may represent a homeostatic negative feedback 
mechanism in which the reduction in MALAT1 limits stiffness-induced proliferation and 
migration. 
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Ingenuity Pathway Predicted 
Categories 
p-value # Molecules MALAT1 NEAT1 DLEU2 
Cell Cycle 3.63E-27 538    
Cellular Growth and Proliferation 4.22E-26 910 X   
Cancer 4.01E-24 2057 X X X 
Organismal Injury and Abnormalities 4.01E-24 2099 X X X 
Cellular Assembly and Organization 4.48E-23 592 X X  
DNA Replication, Recombin., Repair 4.48E-23 454    
Cell Death and Survival 3.86E-22 873 X   
Organismal Survival 2.88E-18 608 X X  
Cellular Development 6.54E-18 806 X   
Post-Translational Modification 1.54E-16 80    
Protein Synthesis 1.54E-16 91    
Cellular Movement 2.71E-12 575 X   
Cellular Function and Maintenance 2.78E-12 431    
Cell Morphology 2.34E-11 528    
Tissue Development 1.40E-10 483    
Cardiovascular Sys Dev. and Func. 3.20E-10 331    
Organismal Development 6.58E-10 698    
Tumor Morphology 5.50E-09 203    
Nucleic Acid Metabolism 2.04E-08 135    
Small Molecule Biochemistry 1.01E-07 113    
Tissue Morphology 1.78E-07 479    
Embryonic Development 2.17E-07 412    
Organ Development 2.17E-07 196    
Organ Morphology 2.17E-07 153    
Skeletal and Muscular Disorders 1.03E-06 115 X   
RNA Post-Transcriptional Modification 1.47E-06 78 X   
Cardiovascular Disease 1.54E-06 416       
 
Table 6. Identification of lncRNA regulators of stiffness-dependent cell responses 
(Predicted Categorical Pathways).  
Top categorical pathways identified in Ingenuity Pathway Analysis. Enrichment p-value 
and number of molecules for each category are listed. An (X) denotes that the 
corresponding lncRNA is represented within that canonical pathway. Only three lncRNAs 
were represented for the top enriched pathways listed (i.e. no other lncRNAs were 
annotated to these pathways in the ingenuity database).
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Ingenuity Pathway Predicted Functions p-value MALAT1 NEAT1 
Proliferation of cells 4.22E-26 X  
Necrosis 3.86E-22 X  
Cell death 1.72E-21 X  
Apoptosis 2.34E-20 X  
Organismal death 2.88E-18 X X 
Morbidity or mortality 3.94E-18 X X 
Metastasis 1.63E-13 X  
Cell movement 2.71E-12 X  
Migration of cells 2.25E-11 X  
Invasion of cells 3.13E-10 X  
Smooth muscle tumor 1.06E-06 X  
Processing of RNA 1.47E-06 X  
Cell transformation 2.7E-06 X  
Organization of organelle 9.24E-06 X  
Formation of nucleus 1.21E-05  X 
Metastasis of cells 3.29E-05 X  
Splicing of RNA 3.55E-05 X  
Leiomyomatosis 0.00012 X  
 
Table 7. Identification of lncRNA regulators of stiffness-dependent cell responses 
(Predicted Functions).  
Top predicted functions identified in Ingenuity Pathway Analysis that contained lncRNAs 
annotated to those functions. Enrichment p-value and for each category are listed. An 
(X) denotes that the corresponding lncRNA is represented within that predicted function. 
MALAT1 and NEAT1 are the only lncRNAs linked to these cellular functions in the 
ingenuity database.  
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Figure 17. MALAT1, a lncRNA regulator of stiffness-dependent cell functions in primary 
VSMCs.  
(A) Left, MALAT1 RNA-seq expression from donor-matched Ao and Co VSMCs. Right, MALAT1 
expression validation by quantitative-PCR in primary Co and Ao VSMCs (n = 5 Co VSMCs, n =4 
Ao VSMCs, **, p < 0.005). (B) MALAT1 knockdown using LNA-GapmeRs in primary Co VSMCs. 
(C) Phase image of primary Co VSMCs cultured on tissue culture plastic for 48 hrs in SmGm2 
after MALAT1 knockdown. Scale bar = 100um. (D) Primary Co VSMCs cultured on soft and stiff 
hydrogels for 48 hours with serum containing EdU. Values are normalized to non-targeting control 
LNA-GapmeR on soft hydrogels (n = 4, ** p<0.005; ****p<0.0001). (E) Normalized median 
velocity, total distance (path-dependent) migrated, and total displacement (path-independent) 
migrated in primary Co VSMCs over 5 hours. Values are normalized to velocity and distance in 
non-targeting control LNA-GapmeR on soft hydrogels. (n = 4, * p<0.05, **p<0.005, Two-way 
ANOVA; Holm-Sidak's multiple comparisons test). 
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Figure 18. MALAT1, a lncRNA regulator of stiffness-dependent cell functions in hTERT-
immortalized Co VSMCs.  
(A) MALAT1 expression validation by quantitative-PCR in primary Co and Ao VSMCs (n = 7, **, p 
< 0.005). (B) MALAT1 knockdown using LNA-GapmeRs in hTERT-Co VSMCs. (C) Phase image 
of hTERT-Co VSMCs cultured on tissue culture plastic for 48 hours in SmGm-2 after MALAT1 
knockdown. Scale bar = 100um. (D) hTERT-Co VSMCs cultured on soft and stiff hydrogels for 48 
hours with serum containing EdU. Values are normalized to non-targeting control LNA-GapmeR 
on soft hydrogels (n = 5, * p<0.05; ** p<0.005). (E) Normalized median velocity, total distance 
(path-dependent), and total displacement (path-independent) migrated in hTERT-VSMCs over 5 
hours. Values are normalized to velocity and distance in non-targeting control LNA-GapmeR on 
soft hydrogels. (n=2-4, * p<0.05, Two-way ANOVA; Holm-Sidak's multiple comparisons test). 
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Figure 19. MALAT1 knockdown inhibits EdU incorporation, cyclin expression and wound 
closure in Co VSMCs on tissue-culture plastic (TCPS).  
(A) Primary and hTERT-immortalized Co VSMCs grown on tissue culture plastic with serum 
containing EdU for 48 hours following LNA-GapmeR knockdown of MALAT1 (n = 4, ** p<0.005, 
*** p<0.0005).  
(B) RT-PCR expression of CCND1 and CCNA1 in hTERT-immortalized Co VSMCs after 
knockdown of MALAT1. Student’s t-test for LNA-control v. LNA-MALAT1-ASO1. (n = 4, *** 
p<0.0005). No statistical test performed for LNA-MALAT1-ASO-2 (n=1). 
(C) Phase images of the closure of the scratch wound in hTERT-immortalized Co VSMCs at 20 
hours post-scratch. 
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DISCUSSION 
Analysis of stiffness-enriched pathways and gene sets for stiffness-sensitive lncRNAs 
allowed us to identify MALAT1 as a lncRNA regulator of VSMC stiffness-dependent 
proliferation and migration. To our knowledge, this is the first study implicating a role for 
MALAT1 in VSMCs and its interplay with matrix stiffness. MALAT1 had previously been 
linked to tumor aggressiveness in in vitro and clinical studies235,246,256,263–267. However, its 
importance in vascular disease is relatively unknown, with only one study implicating 
MALAT1 in endothelial cell function244. While we found that MALAT1-dependent 
proliferation is similar in both VSMCs and endothelial cells, MALAT1 knockdown 
enhances migration in endothelial cells while reducing migration in VSMCs.  
 
Despite many in vitro and in vivo tumor model studies linking MALAT1 to critical cell 
functions, whole-body MALAT1 knockout mice develop normally252–254. We hypothesized 
that MALAT1 may regulate proliferation and migration during pathologic/abnormal 
stiffening but is dispensable during physiologic/normal conditions. In support of this 
stiffness-mediated dependence on MALAT1 hypothesis, our data show that MALAT1 is 
necessary in VSMC proliferation and migration on stiff matrices, but is less important 
under physiologically soft matrices. Most in vitro tumor cell studies interrogating MALAT1 
have been conducted on culture-plastic dishes (orders of magnitude stiffer than tissue). 
Whether this MALAT1-dependence would still be observed in these tumor cell types on 
softer/physiologic stiffness is unknown. As the tumor microenvironment is stiffer than 
normal tissue, and the increased ECM stiffness directly contributes to tumor 
aggressiveness261,262,268–270, perhaps this pathologic stiffening may underlie tumor growth 
and invasion dependence on MALAT1256,263,264,271. Similarly, the dependence of MALAT1 
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in revascularization after ischemic injury may result from post-injury fibrosis244, while 
normal vasculature development in MALAT1-knockout mice is unaffected. Thus, 
vascular stiffening may lead to an aberrant dependence on MALAT1 in VSMCs.  
 
We also find that MALAT1 expression is reduced by ECM stiffness in VSMCs and 
perhaps acts in a negative feedback mechanism to limit stiffness-mediated proliferation 
and migration. However, this effect may not necessarily be universal. RT-PCR validated 
the stiffness-mediated reduction in MALAT1 in the donor-matched Ao and Co VSMCs 
used for the RNAseq. We also validated this finding in several different donors of Ao and 
Co VSMCs, but not in all donors. We believe there may be a level of variability in 
VSMCs from specific donors that exhibit stiffness-mediated MALAT1 reduction while 
others do not. This potential variability may reflect differences in the risk for 
cardiovascular disease from vascular stiffness in various populations272,273. 
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CHAPTER 5: DISCUSSION 
This dissertation was motivated by arterial matrix stiffness, an important clinical 
parameter for disease, but also an important mechanical property dictating cellular 
behavior. We broadly addressed the question of how matrix stiffness regulated the 
transcriptional programs of VSMCs, an important population in responding to and 
promoting matrix stiffness. Many of the findings from this dissertation generated more 
hypotheses than it answered, as is often the case in data-mining, bioinformatic 
approaches. However, we had several a priori goals, including, understanding the 
relative contributions of VSMC embryonic origin and matrix stiffness in regulating the 
transcriptome and identifying novel transcriptional regulators of stiffness-sensing by 
looking at lncRNAs and transcription factors. Working through these initial goals led us 
to analyze transcriptome-wide splicing patterns and experimentally interrogate several 
candidates such as MALAT1, PACER and TBX5. This chapter will put into context the 
findings of the prior chapters in terms of their contributions to basic 
mechanotransduction biology, clinical implications, and in each case, address important 
future directions. 
Basic Mechanotransduction 
From a basic cellular mechanotransduction viewpoint, this dissertation provides insight 
into stiffness-sensitive transcriptome characteristics likely applicable to many cellular 
context, not just VSMCs. We found that stiffness-sensitive genes identified in VSMCs 
are sequence conserved and tend to be expressed across multiple tissues. Thus, the 
stiffness-sensitive transcriptome response, as a whole, may represent a ubiquitous 
response, but whether this is necessarily true will require surveying the stiffness-
sensitive response in multiple, different cell types. It would be interesting to do this 
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analysis in part by integrating the several publicly available datasets of stiffness-
modulated gene expression. Of course, this has its limitations such as batch and 
platform-bias (mostly microarray, few RNA-seq) effects which will need to be accounted 
for, but this combined analysis may help identify ubiquitous vs. cell-specific stiffness-
sensing transcriptional programs. 
This is also the first study to broadly characterize, at a whole transcriptome level, the 
role of stiffness in two classes of transcriptional complexity: alternative splicing and 
lncRNAs. Only one study has previously described stiffness-mediated splicing in one 
gene73, and no study to our knowledge has implicated lncRNAs in the stiffness-
response.  We found that stiffness-dependent lncRNA expression and alternative 
splicing are cell-specific, more so than protein coding gene responses. Whether these 
unique lncRNAs and splicing events confer different phenotypes in Ao and Co VSMCs 
will require further work. We also identified differentially spliced genes (in both Ao and 
Co VSMCs) that may be important in mechanotransduction as they are annotated in 
cytoskeletal processes, but more interestingly, we found that many directly splice out 
their SH3/SH2 domains due to stiffness. The implications of this were discussed in 
Chapter 2. 
Through bioinformatic approaches in Chapter 3, we also identified TBX5 which may be a 
Co VSMC-specific, stiffness-sensitive transcription factor. Indeed, much more will need 
to be studied to validate this hypothesis. A ChIP-qPCR or ChIP-seq for TBX5 will be 
necessary to demonstrate differential promoter binding due to stiffness. Knockdown and 
overexpression of TBX5 will also be necessary to elucidate the functional consequences 
of TBX5 in Co VSMCs and whether documented-TBX5 target genes are indeed 
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activated by stiffness through TBX5. Additionally, direct binding studies between TBX5 
and YAP in Co VSMCs will further strengthen the role of TBX5 in stiffness-sensing.  
Lastly, we focused on lncRNAs that were stiffness-sensitive in both in Ao and Co 
VSMCs: MALAT1 and PACER. 
We found that stiffness represses MALAT1, and that MALAT1 was necessary for 
stiffness-mediated proliferation and migration. Thus, MALAT1 may exist in a feedback 
loop to limit stiffness-responses. However, we suspect that MALAT1 may also contribute 
to the observed stiffness-mediated alternative splicing events. In some cells (e.g. HeLa), 
MALAT1 alters SR splicing factor expression and activity200. Stiffness has been shown to 
phosphorylate and activate SR splicing factors 73. Furthermore, in our VSMC data, we 
found that the expression of many splicing factors including some SR factors were 
stiffness-sensitive, which led to the splicing term enrichment described in Chapter 2. 
Thus, to determine whether MALAT1 coordinates stiffness-mediated splicing in VSMCs, 
a survey of splicing events and splicing factor machinery while modulating MALAT1 in 
VSMC will be required. 
MALAT1 may also regulate epigenetic processes relevant to stiffness-sensing. 
Epigenetic modifications in the form of histone modifications were not interrogated in this 
dissertation, but are mechanosensitive, especially in response to cyclic stretch60. 
MALAT1 has been shown to affect histone modifications and activity of transcriptional 
machinery at growth gene loci241,255. Perhaps MALAT1 may regulate VSMC proliferation 
and migration through such mechanisms. Lastly, MALAT1 has been implicated as a 
competitive endogenous RNA, titrating the effects of microRNAs, some of which target 
known mechanosensitive transcription factors like SRF. Recent evidence also suggest 
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that microRNAs dictate stiffness-mediated responses and may even encode cellular 
memory of exposure to substrate stiffness274,275. It would be interesting if MALAT1 acts 
as a central regulator of mechanotransduction. 
This dissertation also highlights a previously described PACER-PTGS2 axis that is intact 
in several cell types, but is absent from VSMCs during pathologic stiffening. Although 
PACER did not regulate PTGS2 or PLA2G4A, PACER may still regulate other genes 
through its interaction with NFkB, and act as a stimulus-specific lncRNA. An RNA-seq of 
VSMCs with overexpression and knockdown of PACER will be required to determine if 
PACER has any transcriptome-wide consequence in VSMCs or during stiffness-sensing. 
If not, PACER’s function may be cell-type-specific. Indeed, lncRNAs may be expressed 
in a cell type, while having no transcriptional regulatory role in that cell127. PACER-
PTGS2 was identified in a transcriptome-wide correlation analysis, in which we detected 
many highly correlated stiffness-sensitive lncRNA-protein coding gene pairs. How many 
of these are functionally linked versus pure associations will also require further 
investigation. However, the overall observation that stiffness-sensitive lncRNAs are more 
correlated to surrounding genes than stiffness-insensitive genes suggest that some may 
be functionally linked. Our correlation analyses also show that stiffness-sensitive genes 
are often near to other stiffness-sensitive genes, suggesting that regions of 
chromosome, rather than individual genes, may be stiffness-sensitive. 
Clinical/Translational Implications 
Altered cellular functions due to pathologic vascular matrix stiffness manifest as a clinical 
predictor and risk factor for cardiovascular disease. Unlike other risk factors such as 
lipids, blood glucose, and blood pressure, monitoring arterial stiffness is not yet a routine 
clinical parameter. This is likely due to the relative absence and difficulty of developing 
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therapies directly targeting arterial stiffness. However, treatment of dyslipidemia, 
hyperglycemia, and hypertension are often associated with reductions in arterial 
stiffness. For example, angiotensin-2 signaling inhibitors (for hypertension) partially act 
through anti-fibrotic effects, and AGE (advanced glycation end products)-crosslink 
breakers remove non-enzymatic crosslinks due to hyperglycemia276,277. Directly treating 
matrix stiffness is also difficult because it is a critical mechanical property for normal 
vascular function, and in some cases act as a necessary adaptive process to withstand 
changes in hemodynamic load. Unfortunately, systemic inhibition of matrix crosslinkers 
like lysyl oxidase, which is critical in many tissues, can lead to adverse effects like 
vascular dissection and rupture278,279. One option is targeting cellular responses to 
stiffness, such as increased Rho-kinase activity. This is the basis for therapies like 
fasudil, a Rho-kinase inhibitor, which has shown promise in pulmonary artery 
hypertension and atherosclerosis280,281. While the side effect profile of fasudil is fairly low, 
inhibition of Rho-kinase activity has been associated with systemic effects such as 
hypotension282,283. Thus, an ideal therapeutic target for arterial stiffness would be one 
that is dispensable during physiologic elasticity but mediates the effects of pathologic 
stiffening, or one that is cell/tissue-type specific to minimize unintended consequences in 
other tissues.  
Our interrogation of lncRNAs, especially MALAT1, in the stiffness response may 
contribute toward this goal. It appears that MALAT1 is only a critical player during 
pathologic stiffness, and pharmaceutical inhibition of MALAT1 may have limited off-
target effects in non-diseased vasculature. This is supported by the finding that MALAT1 
is dispensable for normal development in mice and becomes functionally relevant during 
several injury models. Our findings in this dissertation support a scenario where 
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pharmaceutical inhibition of MALAT1 could be used to specifically reduce pathologic 
stiffness-driven VSMC proliferation and migration. To test this scenario, inhibition of 
MALAT1, either by MALAT1-knockout or infusion of MALAT1 antisense oligonucleotides 
during in vivo models of stiffening, such as neointimal formation after wire-injury, or an 
atherosclerosis model, would be needed. It must be noted that targeting MALAT1 may 
also lead to inhibition of beneficial regeneration processes such as reperfusion after 
ischemia244. Furthermore, while dispensable during development and early age, it is not 
known whether MALAT1-knockout mice exhibit abnormalities during later adulthood. 
Mouse arteries also progressively stiffen with age and whether MALAT1-knockout mice 
exhibit age-related stiffening will be interesting. Translationally, this is important as the 
incidence of arterial stiffening sharply rises at older age. 
We also identified several variants that were significant in GWAS for vascular diseases. 
These variants were in proximity to FES and MIA3, which were both spliced by stiffness 
in Ao and Co VSMCs. Understanding how the splicing of these two genes and their 
function in the stiffness-response will be a new paradigm for basic mechanotransduction 
biology, but it also may provide insight into why these two genes may be highly 
associated with human vascular diseases. Although the variants discussed in Chapter 2 
were not splicing-quantitative trait loci for FES or MIA3, a deeper analysis of the loci may 
identify other variants within the same haplotype-block that may alter splice-site strength 
or use of an alternative promoter and influence inclusion of a SH2/SH3 domain. If causal 
variants exist for FES and MIA3, this could be clinically important for risk stratification 
and developing therapeutics such as exon-skipping oligonucleotides.  
Lastly, we identified several origin-specific VSMC responses that could be tissue-specific 
therapeutic targets. Stiffness-driven differential splicing was highly VSMC-origin specific. 
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As mentioned above, these specific splicing patterns may be amenable to exon-skipping 
therapies targeting either Ao or Co VSMCs, but their role in pathogenesis will need to be 
studied first. TBX5 is also a Co VSMC-specific transcription factor (although it is also 
expressed in the heart, it is not expressed in other VSMCs). It may be a potential 
therapeutic target with fewer off-target effects than say targeting YAP or SRF, which are 
more ubiquitous. Several TBX5 animal models and human mutations in TBX5 have 
provided detailed understanding of its requirement in development and cardiac 
differentiation, but its role in adulthood is unknown. Inhibiting TBX5 during adulthood 
could lead to cardiac dysfunction if it is required for maintenance. Thus, much about 
TBX5 and whether it has a pathologic role in stiffening and coronary artery disease 
needs to be established. 
In summary, this dissertation integrated an engineered-stiffness culture platform with 
next-generation sequencing and bioinformatics to reveal novel transcriptional properties 
in the Ao and Co VSMC stiffness response, especially in lncRNA and splicing. We 
explored several candidate stiffness-sensitive components and identified potential novel 
mechanotranduction mechanisms. Looking forward, new classes of 
transcriptomic/epigenomic properties and characteristics are being identified, and 
biological data are being generated at exponential rates due to high-throughput 
technology advances. Analyzing and processing these data into digestible information at 
both the systems and gene-specific level will be necessary for meaningful insight and 
better predictions about gene/biological function. Subsequent reductionist approaches 
are still necessary to validate predictions and establish causality, and also feedback to 
improve system level prediction methods. 
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APPENDIX 
Appendix 1. Table of Cardiovascular Disease Traits used in GWAS analyses in Chapter 2 
    Trait Name 
1 
 
Abdominal aortic aneurysm 
2 
 
Aortic root size 
3 
 
Aortic stiffness 
4 
 
Aortic-valve calcification 
5 
 
Arterial stiffness 
6 
 
Blood pressure 
7 
 
Cardiovascular disease risk factors 
8 
 
Cardiovascular heart disease in diabetics 
9 
 
Carotid intima media thickness 
10 
 
Coronary arterial lesions in patients with Kawasaki disease 
11 
 
Coronary artery calcification 
12 
 
Coronary artery disease 
13 
 
Coronary artery disease or ischemic stroke 
14 
 
Coronary artery disease or large artery stroke 
15 
 
Coronary heart disease 
16 
 
Coronary restenosis 
17 
 
Coronary spasm 
18 
 
Diastolic blood pressure 
19 
 
Heart failure 
20 
 
Hypertension 
21 
 
Hypertension (young onset) 
22 
 
Intracranial aneurysm 
23 
 
Large artery stroke 
24 
 
Major CVD 
25 
 
Myocardial infarction 
26 
 
Myocardial infarction (early onset) 
27 
 
Peripheral artery disease 
28 
 
Pulmonary arterial hypertension (without BMPR2 mutations) 
29 
 
Stroke 
30 
 
Stroke (ischemic) 
31 
 
Stroke (pediatric) 
32 
 
Subclinical atherosclerosis traits (other) 
33 
 
Systolic blood pressure 
34 
 
Systolic blood pressure (alcohol consumption interaction) 
35 
 
Thoracic aortic aneurysms and dissections 
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Appendix 2. Ingenuity Pathway Analysis Enriched Upstream “Transcriptional Regulators” 
P-values are determined by Fisher’s Exact Test. Regulators mentioned in the text are 
bolded. Only FDR<1% are shown.
Upstream 
Transcriptional 
Regulator 
p-value of 
overlap 
FDR 
TP53 1.43E-47 3.72E-45 
E2F4 4.53E-47 5.89E-45 
E2F1 6.88E-39 5.96E-37 
CCND1 1.47E-33 9.56E-32 
MYC 2.03E-33 1.06E-31 
NUPR1 2.73E-27 1.18E-25 
CDKN2A 2.10E-26 7.80E-25 
E2F3 2.00E-23 6.50E-22 
TBX2 5.07E-22 1.46E-20 
RB1 2.40E-21 6.24E-20 
MITF 5.05E-18 1.12E-16 
YY1 5.18E-18 1.12E-16 
FOXM1 1.96E-16 3.92E-15 
E2F2 1.16E-14 2.15E-13 
MAX 8.09E-13 1.40E-11 
E2F6 2.51E-12 4.08E-11 
SMARCB1 2.86E-12 4.37E-11 
CREB1 2.40E-11 3.47E-10 
E2F7 3.42E-11 4.68E-10 
MYCN 5.35E-11 6.96E-10 
RBL1 9.31E-11 1.15E-09 
KDM5B 1.19E-10 1.41E-09 
YAP1 2.57E-10 2.91E-09 
NFKBIA 3.74E-10 4.05E-09 
TP73 4.29E-10 4.46E-09 
SMARCA4 5.86E-10 5.86E-09 
HSF1 7.23E-10 6.96E-09 
HNF4A 8.76E-10 8.13E-09 
CTNNB1 9.21E-10 8.26E-09 
CEBPB 2.86E-09 2.48E-08 
HDAC1 1.06E-08 8.89E-08 
E2F8 1.26E-08 1.02E-07 
BRCA1 2.47E-08 1.95E-07 
JUN 3.39E-08 2.59E-07 
SMAD7 5.20E-08 3.86E-07 
GATA1 7.83E-08 5.66E-07 
NKX2-3 9.79E-08 6.88E-07 
FOXO3 1.60E-07 1.09E-06 
EP300 2.57E-07 1.71E-06 
NFYB 2.69E-07 1.72E-06 
FOXO1 2.72E-07 1.72E-06 
NEUROG1 4.19E-07 2.59E-06 
NPAT 6.03E-07 3.65E-06 
TP63 6.42E-07 3.79E-06 
SP1 6.75E-07 3.90E-06 
HIF1A 9.15E-07 5.17E-06 
TAL1 9.36E-07 5.18E-06 
CCNE1 9.87E-07 5.24E-06 
SIN3B 9.87E-07 5.24E-06 
HDAC2 1.34E-06 6.97E-06 
FOS 2.02E-06 1.03E-05 
HOXA10 3.23E-06 1.58E-05 
PAX3 3.23E-06 1.58E-05 
MYBL2 3.49E-06 1.68E-05 
CBX4 4.92E-06 2.33E-05 
TCF3 8.43E-06 3.91E-05 
CUX1 9.69E-06 4.42E-05 
FOXP3 1.31E-05 5.87E-05 
WT1 1.54E-05 6.79E-05 
HTT 2.55E-05 1.10E-04 
MEOX2 2.59E-05 1.10E-04 
APBB1 5.46E-05 2.29E-04 
ATF6 5.89E-05 2.43E-04 
SMARCA2 6.00E-05 2.44E-04 
ATN1 7.22E-05 2.89E-04 
MEF2D 7.60E-05 2.99E-04 
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NFYA 9.13E-05 3.54E-04 
H2AFX 1.17E-04 4.41E-04 
SMARCE1 1.17E-04 4.41E-04 
GLI1 1.19E-04 4.42E-04 
NOTCH1 1.29E-04 4.72E-04 
CREBBP 1.38E-04 4.98E-04 
ARNT 1.43E-04 5.09E-04 
STAT6 1.56E-04 5.48E-04 
TFEB 1.64E-04 5.69E-04 
MED1 1.78E-04 6.01E-04 
TWIST1 1.78E-04 6.01E-04 
TBX5 2.09E-04 6.97E-04 
REL 2.57E-04 8.46E-04 
AIP 2.76E-04 8.96E-04 
UXT 2.79E-04 8.96E-04 
E2F5 2.96E-04 9.39E-04 
SATB1 3.90E-04 1.22E-03 
SQSTM1 4.09E-04 1.27E-03 
VHL 4.84E-04 1.48E-03 
ATXN1 5.06E-04 1.53E-03 
ZNF217 6.07E-04 1.81E-03 
SRSF2 6.63E-04 1.96E-03 
RAD21 6.79E-04 1.98E-03 
ERG 7.63E-04 2.20E-03 
CBX3 8.99E-04 2.57E-03 
CEBPA 1.05E-03 2.94E-03 
EPAS1 1.05E-03 2.94E-03 
HIC1 1.19E-03 3.25E-03 
KLF6 1.19E-03 3.25E-03 
TEAD2 1.20E-03 3.25E-03 
PML 1.24E-03 3.32E-03 
TFDP2 1.25E-03 3.32E-03 
ID3 1.30E-03 3.41E-03 
EZH2 1.37E-03 3.56E-03 
CDKN2C 1.44E-03 3.67E-03 
MEF2C 1.44E-03 3.67E-03 
FHL2 1.48E-03 3.74E-03 
MXI1 1.50E-03 3.75E-03 
MNT 1.56E-03 3.86E-03 
HLX 1.58E-03 3.88E-03 
KLF4 2.02E-03 4.91E-03 
IRX1 2.16E-03 5.13E-03 
PURB 2.16E-03 5.13E-03 
ONECUT1 2.17E-03 5.13E-03 
PDX1 2.23E-03 5.22E-03 
SNAI2 2.25E-03 5.22E-03 
SIN3A 2.30E-03 5.29E-03 
RELA 2.43E-03 5.54E-03 
TFDP1 2.49E-03 5.63E-03 
SMAD4 2.56E-03 5.74E-03 
MYB 2.67E-03 5.93E-03 
HOXA9 2.75E-03 5.95E-03 
KLF2 2.76E-03 5.95E-03 
STAT3 2.76E-03 5.95E-03 
RUNX1 2.77E-03 5.95E-03 
FLI1 2.89E-03 6.16E-03 
PAX7 3.06E-03 6.47E-03 
NFE2L2 3.31E-03 6.94E-03 
ID2 3.40E-03 7.04E-03 
FOSL1 3.41E-03 7.04E-03 
ID4 3.55E-03 7.27E-03 
NOTCH3 4.46E-03 9.06E-03 
MYOCD 4.66E-03 9.39E-03 
SMAD3 4.90E-03 9.80E-03 
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STIFF Enriched 
 
SOFT Enriched 
 
Coronary Aortic Coronary Aortic 
RIBOSOME RIBOSOME ECM_RECEPTOR_INTERACTION LYSOSOME 
SPLICEOSOME SYSTEMIC_LUPUS_ERYTHEMATOSUS LYSOSOME ECM_RECEPTOR_INTERACTION 
SYSTEMIC_LUPUS_ERYTHEMATOSUS SPLICEOSOME FOCAL_ADHESION FOCAL_ADHESION 
HUNTINGTONS_DISEASE DNA_REPLICATION CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION COMPLEMENT_AND_COAGULATION_CASCADES 
PARKINSONS_DISEASE CELL_CYCLE TGF_BETA_SIGNALING_PATHWAY PATHWAYS_IN_CANCER 
PYRIMIDINE_METABOLISM PYRIMIDINE_METABOLISM PATHWAYS_IN_CANCER GLYCOSAMINOGLYCAN_DEGRADATION 
CELL_CYCLE PURINE_METABOLISM GLYCOSAMINOGLYCAN_DEGRADATION ABC_TRANSPORTERS 
OXIDATIVE_PHOSPHORYLATION HOMOLOGOUS_RECOMBINATION COMPLEMENT_AND_COAGULATION_CASCADES TGF_BETA_SIGNALING_PATHWAY 
DNA_REPLICATION HUNTINGTONS_DISEASE NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION PROTEASOME 
PURINE_METABOLISM MISMATCH_REPAIR CELL_ADHESION_MOLECULES_CAMS TOLL_LIKE_RECEPTOR_SIGNALING_PATHWAY 
ALZHEIMERS_DISEASE PARKINSONS_DISEASE BASAL_CELL_CARCINOMA 
EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER
_PYLORI_INFECTION 
AMINOACYL_TRNA_BIOSYNTHESIS RNA_POLYMERASE DILATED_CARDIOMYOPATHY HYPERTROPHIC_CARDIOMYOPATHY_HCM 
RNA_POLYMERASE BASE_EXCISION_REPAIR ABC_TRANSPORTERS INOSITOL_PHOSPHATE_METABOLISM 
HOMOLOGOUS_RECOMBINATION NUCLEOTIDE_EXCISION_REPAIR MAPK_SIGNALING_PATHWAY LEISHMANIA_INFECTION 
OOCYTE_MEIOSIS OXIDATIVE_PHOSPHORYLATION 
ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDI
OMYOPATHY_ARVC 
DILATED_CARDIOMYOPATHY 
NUCLEOTIDE_EXCISION_REPAIR OOCYTE_MEIOSIS HYPERTROPHIC_CARDIOMYOPATHY_HCM PHOSPHATIDYLINOSITOL_SIGNALING_SYSTEM 
MISMATCH_REPAIR AMINOACYL_TRNA_BIOSYNTHESIS WNT_SIGNALING_PATHWAY PPAR_SIGNALING_PATHWAY 
GLYCOLYSIS_GLUCONEOGENESIS RNA_DEGRADATION 
GLYCOSAMINOGLYCAN_BIOSYNTHESIS_CHONDR
OITIN_SULFATE 
MAPK_SIGNALING_PATHWAY 
CITRATE_CYCLE_TCA_CYCLE P53_SIGNALING_PATHWAY HEDGEHOG_SIGNALING_PATHWAY 
ARRHYTHMOGENIC_RIGHT_VENTRICULAR_CARDI
OMYOPATHY_ARVC 
PROGESTERONE_MEDIATED_OOCYT
E_MATURATION 
ALZHEIMERS_DISEASE JAK_STAT_SIGNALING_PATHWAY WNT_SIGNALING_PATHWAY 
BASE_EXCISION_REPAIR 
PROGESTERONE_MEDIATED_OOCYT
E_MATURATION 
EPITHELIAL_CELL_SIGNALING_IN_HELICOBACTER
_PYLORI_INFECTION 
CELL_ADHESION_MOLECULES_CAMS 
RNA_DEGRADATION GLYCOLYSIS_GLUCONEOGENESIS PPAR_SIGNALING_PATHWAY NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION 
PATHOGENIC_ESCHERICHIA_COLI_IN
FECTION 
PATHOGENIC_ESCHERICHIA_COLI_IN
FECTION  
CYTOKINE_CYTOKINE_RECEPTOR_INTERACTION 
UBIQUITIN_MEDIATED_PROTEOLYSIS 
CYSTEINE_AND_METHIONINE_METAB
OLISM  
JAK_STAT_SIGNALING_PATHWAY 
PROTEASOME ONE_CARBON_POOL_BY_FOLATE 
 
GRAFT_VERSUS_HOST_DISEASE 
 
Appendix 3. KEGG enriched pathways. 
Enrichment performed in Gene Set Enrichment Analysis (GSEA, Broad Institute). Listed are the top 25 KEGG Terms per VSMC cell 
type. Enrichment of terms are segregated by Stiff v. Soft based on the rank-order gene list for GSEA. FDR < 1% for all terms. 
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STIFF Enriched STIFF Enriched (Continued)
Coronary Aortic Coronary Aortic
3_UTR_MEDIATED_TRANSLATIONAL_REGULATION 3_UTR_MEDIATED_TRANSLATIONAL_REGULATION MRNA_SPLICING MRNA_SPLICING
ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX ACTIVATION_OF_ATR_IN_RESPONSE_TO_REPLICATION_STRESS MRNA_SPLICING_MINOR_PATHWAY MRNA_SPLICING_MINOR_PATHWAY
AMYLOIDS ACTIVATION_OF_THE_PRE_REPLICATIVE_COMPLEX PACKAGING_OF_TELOMERE_ENDS PACKAGING_OF_TELOMERE_ENDS
CELL_CYCLE AMYLOIDS PEPTIDE_CHAIN_ELONGATION PEPTIDE_CHAIN_ELONGATION
CELL_CYCLE_CHECKPOINTS CELL_CYCLE PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA PROCESSING_OF_CAPPED_INTRON_CONTAINING_PRE_MRNA
CELL_CYCLE_MITOTIC CELL_CYCLE_MITOTIC RESPIRATORY_ELECTRON_TRANSPORT RNA_POL_I_PROMOTER_OPENING
CHROMOSOME_MAINTENANCE CHROMOSOME_MAINTENANCE RNA_POL_I_PROMOTER_OPENING RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION
DNA_REPAIR DNA_REPAIR RNA_POL_I_RNA_POL_III_AND_MITOCHONDRIAL_TRANSCRIPTION RNA_POL_I_TRANSCRIPTION
DNA_REPLICATION DNA_REPLICATION RNA_POL_I_TRANSCRIPTION RNA_POL_II_TRANSCRIPTION
DNA_STRAND_ELONGATION DNA_STRAND_ELONGATION S_PHASE S_PHASE
EXTENSION_OF_TELOMERES EXTENSION_OF_TELOMERES TCA_CYCLE_AND_RESPIRATORY_ELECTRON_TRANSPORT SYNTHESIS_OF_DNA
G1_S_TRANSITION G1_S_SPECIFIC_TRANSCRIPTION TELOMERE_MAINTENANCE TELOMERE_MAINTENANCE
G2_M_CHECKPOINTS G1_S_TRANSITION TRANSCRIPTION TRANSCRIPTION
HIV_INFECTION G2_M_CHECKPOINTS TRANSLATION TRANSLATION
HIV_LIFE_CYCLE HIV_LIFE_CYCLE
INFLUENZA_LIFE_CYCLE INFLUENZA_LIFE_CYCLE
LATE_PHASE_OF_HIV_LIFE_CYCLE LAGGING_STRAND_SYNTHESIS
MEIOSIS LATE_PHASE_OF_HIV_LIFE_CYCLE
MEIOTIC_RECOMBINATION MEIOSIS
MEIOTIC_SYNAPSIS MEIOTIC_RECOMBINATION
METABOLISM_OF_MRNA MEIOTIC_SYNAPSIS
METABOLISM_OF_NON_CODING_RNA METABOLISM_OF_MRNA
METABOLISM_OF_PROTEINS METABOLISM_OF_NON_CODING_RNA
METABOLISM_OF_RNA METABOLISM_OF_PROTEINS
MITOCHONDRIAL_PROTEIN_IMPORT METABOLISM_OF_RNA
MITOTIC_G1_G1_S_PHASES MITOTIC_G1_G1_S_PHASES
MITOTIC_M_M_G1_PHASES MITOTIC_M_M_G1_PHASES
MITOTIC_PROMETAPHASE MITOTIC_PROMETAPHASE
MRNA_PROCESSING MRNA_PROCESSING
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_
MEMBRANE
INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION
NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTI
ON_COMPLEX
FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_T
HE_43S_COMPLEX
FORMATION_OF_THE_TERNARY_COMPLEX_AND_SUBSEQUENTLY_T
HE_43S_COMPLEX
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDI
NG_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S
ACTIVATION_OF_THE_MRNA_UPON_BINDING_OF_THE_CAP_BINDI
NG_COMPLEX_AND_EIFS_AND_SUBSEQUENT_BINDING_TO_43S
DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_T
HE_CENTROMERE
DEPOSITION_OF_NEW_CENPA_CONTAINING_NUCLEOSOMES_AT_
THE_CENTROMERE
INFLUENZA_VIRAL_RNA_TRANSCRIPTION_AND_REPLICATION
TRANSPORT_OF_MATURE_TRANSCRIPT_TO_CYTOPLASM
RESPIRATORY_ELECTRON_TRANSPORT_ATP_SYNTHESIS_BY_CHEMI
OSMOTIC_COUPLING_AND_HEAT_PRODUCTION_BY_UNCOUPLING_
NONSENSE_MEDIATED_DECAY_ENHANCED_BY_THE_EXON_JUNCTI
ON_COMPLEX
SRP_DEPENDENT_COTRANSLATIONAL_PROTEIN_TARGETING_TO_M
EMBRANE
 
Appendix 4. REACTOME Enriched Pathways (STIFF) 
Enrichment performed in Gene Set Enrichment Analysis (GSEA, Broad Institute). Listed are the top Reactome Terms per VSMC cell 
type. Enrichment of terms for STIFF based on the rank-order gene list for GSEA. FDR < 1% for all terms. 
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SOFT Enriched
Coronary Aortic
CHONDROITIN_SULFATE_DERMATAN_SULFATE_METAB
OLISM CHONDROITIN_SULFATE_DERMATAN_SULFATE_METABOLISM
COLLAGEN_FORMATION COLLAGEN_FORMATION
DEVELOPMENTAL_BIOLOGY DIABETES_PATHWAYS
EXTRACELLULAR_MATRIX_ORGANIZATION EXTRACELLULAR_MATRIX_ORGANIZATION
GENERIC_TRANSCRIPTION_PATHWAY GENERIC_TRANSCRIPTION_PATHWAY
GLYCOSAMINOGLYCAN_METABOLISM GLYCOSAMINOGLYCAN_METABOLISM
INTEGRIN_CELL_SURFACE_INTERACTIONS HEPARAN_SULFATE_HEPARIN_HS_GAG_METABOLISM
METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS INNATE_IMMUNE_SYSTEM
NCAM1_INTERACTIONS INTEGRIN_CELL_SURFACE_INTERACTIONS
TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECUL METABOLISM_OF_LIPIDS_AND_LIPOPROTEINS
NCAM1_INTERACTIONS
TRANSMEMBRANE_TRANSPORT_OF_SMALL_MOLECULES
TRANSPORT_OF_GLUCOSE_AND_OTHER_SUGARS_BILE
_SALTS_AND_ORGANIC_ACIDS_METAL_IONS_AND_AM  
Appendix 5. REACTOME Enriched Pathways (SOFT) 
Enrichment performed in Gene Set Enrichment Analysis (GSEA, Broad Institute). Listed are the top Reactome Terms per VSMC cell 
type. Enrichment of terms for SOFT based on the rank-order gene list for GSEA. FDR < 1% for all terms. 
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LncRNA PCG Chr 
Dist 
(kB) 
R 
Corr p-
value 
log2FC 
PCG 
FDR 
PCG 
log2FC 
lncRNA 
FDR 
lncRNA 
LINC00341 SYNE3 14 65.7 0.979 3.98E-11 1.00 3.00E-08 1.41 3.97E-11 
RP11-54O7.1 SAMD11 1 13.4 0.953 1.21E-08 1.06 2.81E-07 1.05 4.44E-04 
AC002116.7 WDR62 19 40.4 0.947 2.72E-08 -2.17 6.48E-41 -1.66 5.07E-04 
RP11-800A3.4 P2RY2 11 20.7 0.944 3.93E-08 2.26 2.63E-18 2.85 1.47E-16 
TMPO-AS1 TMPO 12 0.9 0.944 3.93E-08 -1.72 7.01E-29 -1.97 1.08E-23 
RP11-401P9.4 NKD1 16 97.5 0.938 7.80E-08 2.06 3.23E-08 2.32 3.47E-12 
RP11-386G11.10 TUBA1C 12 61.0 0.935 1.07E-07 -2.21 1.40E-36 -1.97 4.06E-21 
CTD-2269F5.1 EDIL3 5 0.4 0.929 1.94E-07 1.64 4.33E-50 1.17 4.82E-14 
CTB-92J24.2 ZNF726 19 12.9 0.921 4.32E-07 -1.73 7.33E-14 -1.61 3.62E-06 
CTD-2298J14.2 LRFN5 14 2.7 0.921 4.32E-07 1.98 8.04E-09 1.37 1.14E-05 
JHDM1D-AS1 JHDM1D 7 0.2 0.921 4.32E-07 1.62 8.98E-23 1.66 4.01E-18 
RP11-303E16.2 CENPN 16 24.3 0.912 8.82E-07 -1.56 6.61E-37 -1.50 2.28E-22 
RP11-110I1.12 H2AFX 11 97.5 0.903 1.68E-06 -2.11 3.29E-48 -1.03 4.93E-07 
RP5-973M2.2 PTGS2 1 0.2 0.903 1.68E-06 2.23 3.17E-13 1.61 1.28E-11 
RP11-386G11.10 TUBA1B 12 3.6 0.900 2.05E-06 -2.01 4.47E-08 -1.97 4.06E-21 
RP3-462E2.3 ALDH2 12 45.9 0.897 2.49E-06 1.08 2.21E-20 1.78 6.89E-07 
AC009133.12 KIF22 16 30.5 -0.891 3.62E-06 -1.94 2.70E-54 1.18 2.85E-05 
CASC15 SOX4 6 71.0 0.885 5.15E-06 1.74 8.08E-08 1.63 2.35E-14 
RP1-151F17.2 ATXN1 6 2.9 0.885 5.15E-06 1.08 6.09E-23 1.40 3.78E-07 
PRKG1-AS1 DKK1 10 0.2 0.879 7.19E-06 -1.21 5.46E-14 -1.03 5.91E-04 
CTD-2267D19.6 CDC6 17 15.6 0.876 8.44E-06 -1.84 1.61E-23 -1.51 1.09E-08 
RP11-800A3.4 P2RY6 11 25.5 0.876 8.44E-06 1.17 1.68E-06 2.85 1.47E-16 
MCM3AP-AS1 C21orf58 21 94.7 0.874 9.87E-06 -1.27 1.84E-18 -1.12 2.80E-04 
RP4-575N6.4 S1PR1 1 0.4 0.874 9.87E-06 -1.20 1.75E-16 -1.41 1.27E-04 
RP11-1114A5.4 ARHGEF6 X 65.7 0.871 1.15E-05 1.01 4.76E-11 1.88 3.39E-07 
AC005618.6 PCDHGA1 5 4.5 0.865 1.54E-05 1.75 2.83E-13 1.60 1.55E-16 
VPS9D1-AS1 SPATA33 16 54.1 0.862 1.78E-05 -1.01 8.16E-18 -1.93 1.56E-07 
RP11-443B20.1 CENPO 2 32.5 0.859 2.05E-05 -1.71 1.07E-68 -1.34 2.40E-12 
AC005618.6 PCDHGA6 5 47.9 0.856 2.34E-05 1.22 2.34E-10 1.60 1.55E-16 
RP11-134L10.1 TMEM140 7 20.3 0.853 2.68E-05 2.11 2.61E-26 2.16 6.02E-08 
RP11-161H23.5 TUBA1C 12 84.6 0.853 2.68E-05 -2.21 1.40E-36 -2.12 1.06E-08 
RP11-1081L13.4 TMEM86A 11 13.4 0.847 3.42E-05 2.05 8.67E-20 1.87 4.69E-03 
RP11-366L20.3 RP11-366L20.2 12 66.3 0.847 3.47E-05 1.96 5.48E-08 1.76 2.36E-04 
AC005618.6 PCDHGB3 5 44.1 0.841 4.44E-05 1.26 4.72E-10 1.60 1.55E-16 
RP11-161H23.5 C1QL4 12 63.9 0.841 4.44E-05 -1.72 3.18E-04 -2.12 1.06E-08 
RP11-253M7.1 KIF23 15 0.8 0.841 4.44E-05 -2.64 7.25E-40 -1.76 1.92E-10 
RP1-86C11.7 HIST1H2AH 6 23.9 -0.841 4.44E-05 -2.50 6.19E-36 1.84 4.11E-06 
RP11-90B22.1 NRP1 10 5.4 0.834 5.91E-05 1.16 2.83E-12 1.91 2.42E-03 
AC005618.6 PCDHGB4 5 61.7 0.832 6.33E-05 1.14 1.27E-14 1.60 1.55E-16 
AC005618.6 PCDHGB7 5 91.7 0.829 7.09E-05 1.43 2.83E-13 1.60 1.55E-16 
RP1-86C11.7 HIST1H2BJ 6 9.5 -0.826 7.92E-05 -2.03 3.09E-48 1.84 4.11E-06 
AC005618.6 PCDHGB1 5 24.1 0.824 8.84E-05 1.61 4.46E-11 1.60 1.55E-16 
DNAJC3-AS1 DNAJC3 13 0.2 0.824 8.84E-05 1.09 1.98E-25 1.03 2.49E-05 
RP1-86C11.7 HIST1H2AG 6 9.8 -0.824 8.84E-05 -2.48 3.22E-34 1.84 4.11E-06 
CTD-2534I21.8 KIF18B 17 0.2 0.821 9.84E-05 -2.49 2.47E-40 -1.89 9.91E-06 
RP1-43E13.2 MRTO4 1 41.0 -0.821 9.84E-05 -1.29 7.84E-42 1.29 2.97E-04 
RP1-151F17.1 ATXN1 6 0.4 0.818 1.09E-04 1.08 6.09E-23 1.09 5.37E-05 
AC009133.12 SEZ6L2 16 78.3 0.815 1.21E-04 1.26 8.59E-13 1.18 2.85E-05 
RP11-34D15.2 CWF19L1 10 78.7 -0.813 1.27E-04 -1.02 5.80E-27 2.11 1.20E-03 
AC005618.6 PCDHGA10 5 87.0 0.809 1.48E-04 1.18 4.15E-10 1.60 1.55E-16 
RP11-243M5.1 GPR133 12 23.7 0.806 1.63E-04 -1.66 8.86E-17 -1.76 2.05E-03 
RP11-855A2.5 KPNA2 17 39.1 -0.804 1.77E-04 -2.19 8.03E-55 2.47 1.28E-06 
RP11-123O22.1 RP11-180C1.1 4 32.6 0.793 2.46E-04 -2.21 5.15E-18 -1.88 7.55E-06 
RP1-86C11.7 HIST1H4I 6 16.1 -0.791 2.62E-04 -2.64 3.58E-35 1.84 4.11E-06 
RP11-632K5.3 P4HA3 11 0.3 0.785 3.14E-04 1.34 1.81E-08 3.31 5.62E-10 
ACVR2B-AS1 ACVR2B 3 1.0 0.782 3.41E-04 1.35 2.95E-12 1.63 4.68E-05 
AC007743.1 CCDC85A 2 1.6 0.779 3.72E-04 -1.35 9.24E-13 -1.14 4.10E-05 
AC005618.6 PCDHGB2 5 33.9 0.776 4.04E-04 1.25 4.98E-09 1.60 1.55E-16 
RP4-694A7.4 DEPDC1 1 0.5 0.776 4.15E-04 -2.56 3.15E-32 -1.85 2.37E-05 
AC009133.12 PRRT2 16 9.4 0.774 4.39E-04 1.07 1.81E-04 1.18 2.85E-05 
GAS5-AS1 SERPINC1 1 54.1 0.771 4.77E-04 1.01 3.42E-03 1.41 1.77E-04 
LINC01059 GRAMD1B 11 71.2 0.771 4.77E-04 1.27 6.68E-10 1.18 1.57E-05 
RP1-86C11.7 HIST1H2BK 6 23.6 -0.771 4.77E-04 -1.33 3.43E-25 1.84 4.11E-06 
RP11-92C4.6 COL15A1 9 0.6 0.767 5.30E-04 2.47 5.58E-35 1.37 3.88E-03 
RP11-135L13.4 RNF112 17 75.0 0.765 5.60E-04 2.13 4.57E-10 1.06 4.30E-03 
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RP11-490M8.1 CRIM1 2 0.8 0.762 6.05E-04 -1.01 3.82E-19 -1.58 1.20E-13 
OSER1-AS1 JPH2 20 23.4 -0.756 7.06E-04 -1.62 2.68E-05 1.08 2.38E-10 
GAS5-AS1 CENPL 1 38.5 -0.753 7.61E-04 -1.64 1.36E-26 1.41 1.77E-04 
RP11-161H23.5 TROAP 12 49.9 0.753 7.61E-04 -2.91 1.49E-61 -2.12 1.06E-08 
RP11-690G19.3 PLXDC1 17 99.9 0.753 7.61E-04 1.16 8.25E-03 1.56 3.34E-20 
ANKRD10-IT1 ANKRD10 13 15.9 0.744 9.48E-04 1.53 1.42E-15 1.38 9.71E-05 
 
Appendix 6. Correlated Stiffness-sensitive lncRNA-Protein Coding Gene Pairs 
Spearman’s correlation (R) for stiffness-sensitive lncRNA and protein coding genes (PCG) on the 
same chromosome (Chr). The distance (Dist) between their annotated gene start coordinates is 
shown in kilobases. Log2FC for LncRNA and PCG represent the combined Ao and Co VSMC 
data. Log2FC and FDR calculated based on grouping soft and stiff groups together, independent 
to cell-type. Only correlation p-values < 1e-5 are included. 
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